Document:

Exhibit 10.1

 

SECURITIES PURCHASE AGREEMENT

 

This Securities Purchase
Agreement (this “Agreement”) is dated as of June 30, 2015 by and among Transgenomic, Inc., a Delaware
corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including
its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).

 

RECITALS

 

A.           The
Company and each Purchaser is executing and delivering this Agreement in reliance upon the exemption from securities registration
afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and
Rule 506 of Regulation D (“Regulation D”) as promulgated by the United States Securities and Exchange
Commission (the “Commission”) under the Securities Act.

 

B.           Each
Purchaser, severally and not jointly, wishes to purchase, and the Company wishes to sell, upon the terms and conditions stated
in this Agreement, (i) that aggregate number of shares of common stock, par value $0.01 per share (the “Common
Stock”), of the Company, set forth below such Purchaser’s name on the signature page of this Agreement (which
aggregate amount for all Purchasers together shall be up to 2,140,676 shares of Common Stock and shall be collectively referred
to herein as the “Shares”), (ii) Series A warrants, in substantially the form attached hereto as
Exhibit A (the “Series A Warrants”), to acquire up to that number of additional shares of Common
Stock equal to 55% of the number of Shares purchased by such Purchaser, rounded up to the nearest whole share and (iii) Series
B warrants, in substantially the form attached hereto as Exhibit B (the “Series B Warrants”),
to acquire up to that number of additional shares of Common Stock set forth on the signature pages hereto, rounded up to the nearest
whole share (the Series A and Series B Warrants are collectively referred to as the “Warrants” and the
shares of Common Stock issuable upon exercise of or otherwise pursuant to the Warrants collectively are referred to herein as the
“Warrant Shares”).

 

C.           The
Shares, the Warrants and the Warrant Shares collectively are referred to herein as the “Securities”.

 

D.           The
Company has engaged Craig-Hallum Capital Group LLC to act as the placement agent (the “Placement Agent”)
for the offering of the Shares and Warrants on a “best efforts” basis.

 

E.           Contemporaneously
with the execution and delivery of this Agreement, the parties hereto are executing and delivering a Registration Rights Agreement,
substantially in the form attached hereto as Exhibit B (the “Registration Rights Agreement”),
pursuant to which, among other things, the Company will agree to provide certain registration rights with respect to the Shares
and the Warrant Shares under the Securities Act and the rules and regulations promulgated thereunder and applicable state securities
laws.

 

NOW, THEREFORE, IN
CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and
adequacy of which are hereby acknowledged, the Company and each Purchaser hereby agree as follows:

 

    	 

    	 

    

  

ARTICLE
I

DEFINITIONS

 

1.1           Definitions.
In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms shall have
the meanings indicated in this Section 1.1:

 

“Accredited
Investor Questionnaire” means the Accredited Investor Questionnaire set forth as Exhibit C-1 hereto.

 

“Action”
means any action, suit, inquiry, notice of violation, proceeding (including any partial proceeding such as a deposition) or investigation
pending or, to the Company’s Knowledge, threatened against the Company, any of its properties, or any officer, director or
employee of the Company acting in his or her capacity as an officer, director or employee before or by any federal, state, county,
local or foreign court, arbitrator, governmental or administrative agency, regulatory authority, stock market, stock exchange or
trading facility.

 

“Affiliate”
means, with respect to any Person, any other Person that, directly or indirectly through one or more intermediaries, controls,
is controlled by or is under common control with such Person; as such terms are used in and construed under Rule 405 under the
Securities Act. With respect to a Purchaser, any investment fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be an Affiliate of such Purchaser.

 

“Agreement”
has the meaning set forth in the Preamble.

 

“Board
of Directors” means the board of directors of the Company.

 

“Business
Day” means any day except Saturday, Sunday, any day which is a federal legal holiday in the United States or any
day on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.

 

“Buy-In”
has the meaning set forth in Section 4.1(f).

 

“Buy-In
Price” has the meaning set forth in Section 4.1(f).

 

“Closing”
means the closing of the purchase and sale of the Shares and the Warrants on the Closing Date pursuant to Section 2.1.

 

    	2

    	 

    

 

“Closing
Bid Price” means, for any security as of any date, (a) the last reported closing bid price per share for such
security on the Principal Trading Market, as reported by Bloomberg Financial Markets, or (b) if the Principal Trading Market
begins to operate on an extended hours basis and does not designate the closing bid price then the last bid price of such security
prior to 4:00 p.m., New York City time, as reported by Bloomberg Financial Markets, or (c) if the foregoing do not apply,
the last closing price of such security in the over-the-counter market on the electronic bulletin board for such security as reported
by Bloomberg Financial Markets, or (d) if no closing bid price is reported for such security by Bloomberg Financial Markets,
the average of the bid prices of any market makers for such security as reported on OTC Pink (also known as the “pink sheets”)
by the OTC Markets, Inc. If the Closing Bid Price cannot be calculated for a security on a particular date on any of the foregoing
bases, the Closing Bid Price of such security on such date shall be the fair market value as mutually determined by the Company
and the holder of such security. If the Company and such holder are unable to agree upon the fair market value of such security,
then the Board of Directors shall use its good faith judgment to determine the fair market value. The Board of Directors’
determination shall be binding on all parties absent demonstrable error. All such determinations shall be appropriately adjusted
for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period.

 

“Closing
Date” means the Trading Day on which all of the Transaction Documents have been executed and delivered by the applicable
parties thereto, and all of the conditions set forth in Sections 2.2, 5.1 and 5.2 hereof are satisfied or
waived, as the case may be, or such other date as the parties may agree.

 

“Commission”
has the meaning set forth in the Recitals.

 

“Common
Stock” has the meaning set forth in the Recitals, and also includes any other class of securities into which the
Common Stock may hereafter be reclassified or changed.

 

“Common
Stock Equivalents” means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at
any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock or other securities
that entitle the holder to receive, directly or indirectly, Common Stock.

 

“Company”
has the meaning set forth in the Preamble.

 

“Company
Counsel” means Paul Hastings LLP, with offices located at 1117 S. California Avenue, Palo Alto, California 94304.

 

“Company
Deliverables” has the meaning set forth in Section 2.2(a).

 

“Company’s
Knowledge” means, with respect to any statement made to the Company’s Knowledge, that the statement is based
upon the actual knowledge of the executive officers of the Company (as defined in Rule 405 under the Securities Act) having responsibility
for the matter or matters that are the subject of the statement.

 

“Deadline
Date” has the meaning set forth in Section 4.1(f).

 

“Disclosure
Materials” has the meaning set forth in Section 3.1(h).

 

“Disclosure
Schedules” has the meaning set forth in Section 3.1.

 

“DTC”
has the meaning set forth in Section 4.1(c).

 

“Effective
Date” means the date on which the initial Registration Statement required by Section 2(a) of the Registration
Rights Agreement is first declared effective by the Commission.

 

    	3

    	 

    

  

“Environmental
Laws” has the meaning set forth in Section 3.1(cc).

 

“Escrow
Agent” means Private Bank Minnesota, a Minnesota banking corporation.

 

“Escrow
Agreement” means the escrow agreement, by and among the Company, the Escrow Agent and the Placement Agent pursuant
to which the Purchasers shall deposit Subscription Amounts with the Escrow Agent to be applied to the transactions contemplated
hereunder.

 

“Evaluation
Date” has the meaning set forth in Section 3.1(s).

 

“Exchange
Act” means the Securities Exchange Act of 1934, as amended, or any successor statute, and the rules and regulations
promulgated thereunder.

 

“FDA”
has the meaning set forth in Section 3.1(kk).

 

“Fund”
has the meaning set forth in Section 3.2(k).

 

“GAAP”
means U.S. generally accepted accounting principles, as applied by the Company.

 

“Governmental
Licenses” has the meaning set forth in Section 3.1(kk).

 

“Indemnified
Person” has the meaning set forth in Section 4.9.

 

“Intellectual
Property Rights” has the meaning set forth in Section 3.1(o).

 

“Irrevocable
Transfer Agent Instructions” means, with respect to the Company, the Irrevocable Transfer Agent Instructions, in
substantially the form of Exhibit D, executed by the Company and delivered to and acknowledged in writing by the Transfer
Agent.

 

“Lien”
means any lien, charge, deed of trust, claim, encumbrance, security interest, priority, right or preferential arrangement of any
kind or nature whatsoever (excluding preferred stock and equity related preferences) or other restrictions of any kind.

 

“Lockup
Agreements” means the Lockup Agreements from certain directors, officers and major stockholders in the form of Exhibit
H hereto.

 

“Material
Adverse Effect” means a material adverse effect on the results of operations, assets, prospects, business or financial
condition of the Company and the Subsidiaries, taken as a whole, except that any of the following, either alone or in combination,
shall not be deemed a Material Adverse Effect: (a) effects caused by changes or circumstances affecting general market conditions
in the U.S. economy or which are generally applicable to the industry in which the Company operates, provided that such effects
are not borne disproportionately by the Company; (b) effects caused by earthquakes, hostilities, acts of war, sabotage or
terrorism or military actions or any escalation or material worsening of any such hostilities, acts of war, sabotage or terrorism
or military actions existing as of the date hereof; (c) effects resulting from or relating to the announcement or disclosure
of the sale of Securities or other transactions contemplated by this Agreement; or (d) effects caused by any event, occurrence
or condition resulting directly from or directly relating to the taking of any action as required in accordance with this Agreement.

 

    	4

    	 

    

  

“Material
Contract” means any contract of the Company that has been filed or was required to have been filed as an exhibit
to the SEC Reports pursuant to Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.

 

“New York
Courts” means the state and federal courts sitting in the City of New York, Borough of Manhattan.

 

“OFAC”
has the meaning set forth in Section 3.1(jj).

 

“Outside
Date” means the 10th Business Day following the date of this Agreement.

 

“Person”
means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company,
joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically
listed herein.

 

“Placement
Agent” has the meaning set forth in the Recitals.

 

“Press
Release” has the meaning set forth in Section 4.5.

 

“Principal
Trading Market” means the Trading Market on which the Common Stock is primarily listed and quoted for trading, which,
as of the date of this Agreement and the Closing Date, shall be the NASDAQ Capital Market.

 

“Proceeding”
means an action, claim, suit, investigation or proceeding (including, without limitation, an investigation or partial proceeding,
such as a deposition), whether commenced or threatened.

 

“Purchase
Price” means $1.42 for each share of Common Stock and the related Series A and Series B Warrants to be purchased
hereunder, subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar transactions
of the Common Stock that occur after the date of this Agreement.

 

“Purchaser”
or “Purchasers” has the meaning set forth in the Recitals.

 

“Purchaser
Deliverables” has the meaning set forth in Section 2.2(b).

 

“Purchaser
Party” has the meaning set forth in Section 4.9.

 

“Registration
Rights Agreement” has the meaning set forth in the Recitals.

 

“Registration
Statement” means a registration statement meeting the requirements set forth in the Registration Rights Agreement
and covering the resale by the Purchasers of the Registrable Securities (as defined in the Registration Rights Agreement).

 

    	5

    	 

    

  

“Regulation
D” has the meaning set forth in the Recitals.

 

“Required
Approvals” has the meaning set forth in Section 3.1(e).

 

“Rule 144”
means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such rule may be amended from time to time, or
any similar rule or regulation hereafter adopted by the Commission having substantially the same effect as such rule.

 

“SEC Reports”
has the meaning set forth in Section 3.1(h).

 

“Secretary’s
Certificate” has the meaning set forth in Section 2.2(a)(vii).

 

“Securities”
has the meaning set forth in the Recitals.

 

“Securities
Act” has the meaning set forth in the Recitals.

 

“Shares”
has the meaning set forth in the Recitals.

 

“Short
Sales” has the meaning set forth in Section 3.2(k).

 

“Stock
Certificates” has the meaning set forth in Section 2.2(a)(ii).

 

“Subscription
Amount” means, with respect to each Purchaser, the aggregate amount to be paid for the Shares and the related Warrants
purchased hereunder as indicated on such Purchaser’s signature page to this Agreement next to the heading “Aggregate
Purchase Price (Subscription Amount)” in United States dollars and in immediately available funds.

 

“Subsidiary”
means any subsidiary of the Company as set forth on Schedule 3.1(a), and shall, where applicable, include any corporation,
partnership, limited liability company, joint venture or other legal entity, formed or acquired by the Company after the date hereof,
provided that the Company owns directly or indirectly, more than 50% of the stock or other equity interests of such corporation
or other legal entity.

 

“Trading
Day” means (a) a day on which the Common Stock is listed or quoted and traded on its Principal Trading Market,
or (b) if the Common Stock is not listed on a Trading Market, a day on which the Common Stock is traded in the over-the-counter
market, as reported by the OTC Markets, Inc. (or any similar organization or agency succeeding to its functions of reporting prices);
provided, that in the event that the Common Stock is not listed or quoted as set forth in (a) or (b) hereof, then
Trading Day shall mean a Business Day.

 

“Trading
Market” means whichever of the NYSE MKT LLC, the NASDAQ Global Select Market, the NASDAQ Global Market or the NASDAQ
Capital Market on which the Common Stock is listed or quoted for trading on the date in question.

 

“Transaction
Documents” means this Agreement, the schedules and exhibits attached hereto, the Warrants, the Registration Rights
Agreement, the Irrevocable Transfer Agent Instructions and any other documents or agreements explicitly contemplated hereunder.

 

    	6

    	 

    

 

“Transfer
Agent” means Wells Fargo Shareowner Services, the current transfer agent of the Company, with a mailing address of
1110 Centre Pointe Curve, Suite 101, Mendota Heights, MN 55120, and a telephone number of (855) 217-6361, or any successor transfer
agent for the Company.

 

“Warrants”
has the meaning set forth in the Recitals. The Placement Agent (as defined below) and/or its designees are also receiving placement
agent warrants as compensation for services rendered in connection with the transactions set forth herein, which warrants shall
also constitute “Warrants” for all purposes hereunder.

 

“Warrant
Shares” has the meaning set forth in the Recitals.

 

ARTICLE
II

PURCHASE AND SALE

 

2.1          Closing.

 

(a)          Amount.
Subject to the terms and conditions set forth in this Agreement, at the Closing, the Company shall issue and sell to each Purchaser,
and each Purchaser shall, severally and not jointly, purchase from the Company, (i) that number of Shares equal to the quotient
resulting from dividing (A) the Subscription Amount for such Purchaser’s Shares shown on the signature pages hereto by (B)
the Purchase Price, rounded up to the nearest whole Share, (ii) Series A Warrants to acquire up to that number of Warrant
Shares equal to 55% of the number of Shares and Series B Warrants purchased by such Purchaser, rounded up to the nearest whole
Warrant Share; and (iii) that number of Series B Warrants shown on the signature pages hereto; provided, however,
that in the event any Purchasers are Affiliates of each other, all Shares purchased by such Purchasers shall be aggregated together
for the purpose of determining the aggregate number of Warrant Shares subject to all Warrants purchased by such Purchasers. The
Series A Warrants shall have an exercise price equal to $1.66 per Warrant Share, subject to adjustment as provided in such Warrants;
and the Series B Warrants shall have an exercise price of $0.01 per Series B Warrant Share, subject to adjustment as provided in
such Warrants.

 

(b)          Closing.
The Closing of the purchase and sale of the Shares and Warrants shall take place at the offices of Paul Hastings LLP, located at
1117 S. California Avenue, Palo Alto, California 94304 at 10:00 a.m. local time on the Closing Date or at such other location(s)
or remotely by facsimile transmission or other electronic means as the parties may mutually agree.

 

(c)          Form
of Payment. Except as may otherwise be agreed to among the Company and one or more of the Purchasers, on or prior to the Business
Day immediately prior to the Closing Date, each Purchaser shall wire its Subscription Amount, in United States dollars and in immediately
available funds, in accordance with the wire instructions specified in writing in the Escrow Agreement. On the Closing Date, the
Company shall (a) pay to the Placement Agent its respective fees and reimbursable expenses payable to the Placement Agent,
(b) the Transfer Agent shall deliver to or as directed by the Placement Agent by 9:00 a.m. (New York City time) one or more
stock certificates for each Purchaser, free and clear of all restrictive and other legends (except as expressly provided in Section
4.1(b)), evidencing the number of Shares each Purchaser is purchasing as set forth on such Purchaser’s signature page
to this Agreement next to the heading “Number of Shares to be Acquired” and (c) the Company shall deliver to or
as directed by the Placement Agent by 9:00 a.m. (New York City time) one or more Warrants for each Purchaser, free and clear of
all restrictive and other legends (except as expressly provided in Section 4.1(b)), evidencing the number of Warrant
Shares each Purchaser is entitled to purchase as set forth on such Purchaser’s signature page to this Agreement next to the
heading “Underlying Shares Subject to Warrant.”

 

    	7

    	 

    

  

2.2          Closing
Deliveries.

 

(a)          On
or prior to the Closing, the Company shall issue, deliver or cause to be delivered to each Purchaser (except as noted), the following
(the “Company Deliverables”):

 

(i)          this
Agreement, duly executed by the Company;

 

(ii)         original
stock certificates, free and clear of all restrictive and other legends (except as provided in Section 4.1(b)), evidencing
the Shares subscribed for by such Purchaser, as calculated in accordance with Section 2.1(a), registered in the name
of such Purchaser as set forth on the Stock Certificate Questionnaire included as Exhibit C-2 hereto (the “Stock
Certificates”), to be delivered by the Transfer Agent to or as directed by the Placement Agent on or before 9:00
a.m. (New York City time) of the Closing Date (for further delivery by the Placement Agent to the applicable Purchaser upon Closing);

 

(iii)        original
Series A Warrants and Series B Warrants, executed by the Company and registered in the name of such Purchaser as set forth on the
Stock Certificate Questionnaire included as Exhibit C-2 hereto, pursuant to which such Purchaser shall have the
right to acquire such number of Warrant Shares subscribed for by such Purchaser, as calculated in accordance with Section
2.1(a), on the terms set forth therein, to be delivered by the Company to or as directed by the Placement Agent on or before
9:00 a.m. (New York City time) of the Closing Date (for further delivery by the Placement Agent to the applicable Purchaser upon
Closing);

 

(iv)         a
legal opinion of Company Counsel, dated as of the Closing Date and in substantially the form attached hereto as Exhibit E,
executed by such counsel and addressed to the Purchasers;

 

(v)          the
Registration Rights Agreement, duly executed by the Company;

 

(vi)         duly
executed Irrevocable Transfer Agent Instructions acknowledged in writing by the Transfer Agent;

 

(vii)        a
certificate of the Secretary of the Company (the “Secretary’s Certificate”), dated as of the Closing
Date and in substantially the form attached hereto as Exhibit F;

 

(viii)      the
Lockup Agreements, executed by the parties thereto;

 

(ix)         the
Compliance Certificate referred to in Section 5.1(h);

 

    	8

    	 

    

  

(x)          a
certificate evidencing the incorporation and good standing of the Company issued by the Secretary of State of the State of Delaware
as of a date within five days of the Closing Date;

 

(xi)         certificates
evidencing the Company’s qualification as a foreign corporation and good standing issued by the Secretary of State of the
State of Nebraska as of a date within 10 days of the Closing Date;

 

(xii)        a
certified copy of the certificate of incorporation of the Company, as certified by the Secretary of State of the State of Delaware,
as of a date within 10 days of the Closing Date; and

 

(xiii)      evidence
reasonably satisfactory to each Purchaser that the Shares and the Warrant Shares have been approved for listing on the NASDAQ Capital
Market, subject to official notice of issuance.

 

(b)          On
or prior to the Closing, each Purchaser shall deliver or cause to be delivered to the Company, or the Escrow Agent, as applicable,
the following, with respect to such Purchaser (the “Purchaser Deliverables”):

 

(i)          this
Agreement, duly executed by such Purchaser;

 

(ii)         to
the Escrow Agent, its Subscription Amount, in United States dollars and in immediately available funds, in the amount set forth
below such Purchaser’s name on the applicable signature page hereto under the heading “Aggregate Purchase Price (Subscription
Amount)” by wire transfer to the account specified in the Escrow Agreement;

 

(iii)        the
Registration Rights Agreement, duly executed by such Purchaser; and

 

(iv)         a
fully completed and duly executed Accredited Investor Questionnaire, satisfactory to the Company, and Stock Certificate Questionnaire,
in the forms attached hereto as Exhibits C-1 and C-2, respectively.

 

ARTICLE
III

REPRESENTATIONS AND WARRANTIES

 

3.1           Representations
and Warranties of the Company. Except as (i) set forth in the schedules delivered herewith (the “Disclosure
Schedules”), which Disclosure Schedules shall be deemed a part hereof and shall qualify any representation made herein
to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules or other representations relating
to the subject matter of such disclosures, or (ii) specifically disclosed in the SEC Reports, which shall be deemed to qualify
any representation made herein that specifically references such SEC Reports, the Company hereby represents and warrants as of
the date hereof and the Closing Date (except for the representations and warranties that speak as of a specific date, which shall
be made as of such date), to each of the Purchasers and to the Placement Agent:

 

    	9

    	 

    

  

(a)          Subsidiaries.
The Company has no direct or indirect subsidiaries other than those listed in Schedule 3.1(a) hereto. Except as disclosed
in Schedule 3.1(a) hereto, the Company owns, directly or indirectly, all of the capital stock or comparable equity
interests of each Subsidiary free and clear of any and all Liens, and all the issued and outstanding shares of capital stock or
comparable equity interests of each Subsidiary are validly issued and are fully paid, non-assessable and free of preemptive and
similar rights to subscribe for or purchase securities.

 

(b)          Organization
and Qualification. The Company and each of its Subsidiaries is an entity duly incorporated or otherwise organized, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or organization (as applicable), with the
requisite corporate power and authority to own or lease and use its properties and assets and to carry on its business as currently
conducted. Neither the Company nor any Subsidiary is in violation or default of any of the provisions of its respective certificate
of incorporation or bylaws or other organizational documents. The Company and each of its Subsidiaries is duly qualified to conduct
business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the nature of the business
conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing,
as the case may be, would not have or reasonably be expected to result in a Material Adverse Effect, and no Proceeding has been
instituted, is pending, or, to the Company’s Knowledge, has been threatened in any such jurisdiction revoking, limiting or
curtailing or seeking to revoke, limit or curtail such power and authority or qualification.

 

(c)          Authorization;
Enforcement; Validity. The Company has the requisite corporate power and authority to enter into and to consummate the transactions
contemplated by each of the Transaction Documents to which it is a party and otherwise to carry out its obligations hereunder and
thereunder. The Company’s execution and delivery of each of the Transaction Documents to which it is a party and the consummation
by it of the transactions contemplated hereby and thereby (including, but not limited to, the sale and delivery of the Shares and
the reservation for issuance and the subsequent issuance of the Warrant Shares upon exercise of the Warrants) have been duly authorized
by all necessary corporate action on the part of the Company, and no further corporate action is required by the Company, its Board
of Directors or its stockholders in connection therewith other than in connection with the Required Approvals. Each of the Transaction
Documents to which it is a party has been (or upon delivery will have been) duly executed by the Company and is, or when delivered
in accordance with the terms hereof, will constitute the legal, valid and binding obligation of the Company enforceable against
the Company in accordance with its terms, except (i) as such enforceability may be limited by applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’
rights and remedies or by other equitable principles of general application, (ii) as limited by laws relating to the availability
of specific performance, injunctive relief or other equitable remedies, and (iii) insofar as indemnification and contribution
provisions may be limited by applicable law.

 

    	10

    	 

    

 

(d)          No
Conflicts. The execution, delivery and performance by the Company of the Transaction Documents to which it is a party and the
consummation by the Company of the transactions contemplated hereby or thereby (including, without limitation, the issuance of
the Shares and Warrants and the reservation for issuance and issuance of the Warrant Shares) do not and will not (i) conflict
with or violate any provisions of the Company’s or any Subsidiary’s certificate of incorporation or bylaws or otherwise
result in a violation of the organizational documents of the Company, (ii) conflict with, or constitute a default (or an event
that with notice or lapse of time or both would result in a default) under, result in the creation of any Lien upon any of the
properties or assets of the Company or any Subsidiary or give to others any rights of termination, amendment, acceleration or cancellation
(with or without notice, lapse of time or both) of, any Material Contract, or (iii) subject to the Required Approvals, conflict
with or result in a violation of any law, rule, regulation, order, judgment, injunction, decree or other restriction of any court
or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations
and the rules and regulations, assuming the correctness of the representations and warranties made by the Purchasers herein, of
any self-regulatory organization to which the Company or its securities are subject, including all applicable Trading Markets),
or by which any property or asset of the Company is bound or affected, except in the case of clauses (ii) and (iii) such
as would not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect or a material
adverse effect on the legality, validity or enforceability of any Transaction Document or the Company’s ability to perform
in any material respect on a timely basis its obligations under any Transaction Document.

 

(e)          Filings,
Consents and Approvals. Neither the Company nor any of its Subsidiaries is required to obtain any consent, waiver, approval,
authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local
or other governmental authority, holder of outstanding securities of the Company or other Person in connection with the execution,
delivery and performance by the Company of the Transaction Documents (including the issuance of the Securities), other than (i) the
filing with the Commission of one or more Registration Statements in accordance with the requirements of the Registration Rights
Agreement, (ii) filings required by applicable state securities laws, (iii) the filing of a Notice of Sale of Securities
on Form D with the Commission under Regulation D of the Securities Act, (iv) the filing of any requisite notices and/or application(s)
to the Principal Trading Market for the issuance and sale of the Securities and the listing of the Shares and Warrant Shares for
trading or quotation, as the case may be, thereon in the time and manner required thereby, (v) the filings required in accordance
with Section 4.5, and (vi) those that have been made or obtained prior to the date of this Agreement (collectively,
the “Required Approvals”).

 

(f)          Issuance
of the Securities. The Shares have been duly authorized and, when issued and paid for in accordance with the terms of the Transaction
Documents, will be duly and validly issued, fully paid and nonassessable and free and clear of all Liens, other than restrictions
on transfer provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive
or similar rights of stockholders. The Warrants have been duly authorized and, when issued and paid for in accordance with the
terms of the Transaction Documents, will be duly and validly issued, free and clear of all Liens, other than restrictions on transfer
provided for in the Transaction Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar
rights of stockholders. The Warrant Shares issuable upon exercise of the Warrants have been duly authorized and reserved and, when
issued and paid for in accordance with the terms of the Transaction Documents and the Warrants, will be duly and validly issued,
fully paid and nonassessable, free and clear of all Liens, other than restrictions on transfer provided for in the Transaction
Documents or imposed by applicable securities laws, and shall not be subject to preemptive or similar rights of stockholders. Assuming
the accuracy of the representations and warranties of the Purchasers in this Agreement, the Securities will be issued in compliance
with all applicable federal and state securities laws. The Company shall, so long as any of the Warrants are outstanding, take
all action necessary to reserve and keep available out of its authorized and unissued capital stock, solely for the purpose of
effecting the exercise of the Warrants, the number of shares of Common Stock issuable upon exercise of the Warrants (without taking
into account any limitations on the exercise of the Warrants set forth in the Warrants).

 

    	11

    	 

    

  

(g)          Capitalization.
The capitalization of the Company is as described in its most recently filed SEC Report on Form 10-Q, except for issuances pursuant
to this Agreement, stock option exercises, issuances pursuant to equity incentive plans or exercises of warrants. The Company has
not issued any capital stock since the date of its most recently filed SEC Report other than to reflect stock option and warrant
exercises that do not, individually or in the aggregate, have a material effect on the issued and outstanding capital stock, options
and other securities of the Company. No Person has any right of first refusal, preemptive right, right of participation, or any
similar right to participate in the transactions contemplated by the Transaction Documents that have not been effectively waived
as of the Closing Date. Except as set forth on Schedule 3.1(g), or as a result of the purchase and sale of the Shares and
Warrants, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities, rights or obligations convertible into or exercisable or exchangeable for, or giving any Person any
right to subscribe for or acquire any shares of Common Stock, or contracts, commitments, understandings or arrangements by which
the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents. Except
as set forth on Schedule 3.1(g), the issuance and sale of the Shares and Warrants will not obligate the Company to issue
shares of Common Stock or other securities to any Person (other than the Purchasers) and will not result in a right of any holder
of Company securities to adjust the exercise, conversion, exchange or reset price under any of such securities. All of the outstanding
shares of capital stock of the Company are validly issued, fully paid and nonassessable, have been issued in compliance in all
material respects with all applicable federal and state securities laws, and none of such outstanding shares was issued in violation
of any preemptive rights or similar rights to subscribe for or purchase securities which violation would have or would reasonably
be expected to result in a Material Adverse Effect. No further approval or authorization of any stockholder, the Board of Directors
or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other
similar agreements with respect to the Company’s capital stock to which the Company is a party or, to the Company’s
Knowledge, between or among any of the Company’s stockholders.

 

    	12

    	 

    

 

(h)          SEC
Reports; Disclosure Materials. The Company has filed all reports, schedules, forms, statements and other documents required
to be filed by it under the Exchange Act, including pursuant to Section 13(a) or 15(d) thereof, for the 12 months preceding
the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing
materials, including the exhibits thereto and documents incorporated by reference therein, being collectively referred to herein
as the “SEC Reports”, and the SEC Reports, together with the Disclosure Schedules, being collectively
referred to as the “Disclosure Materials”) on a timely basis or has received a valid extension of such
time of filing and has filed any such SEC Reports prior to the expiration of any such extension, except where the failure to file
on a timely basis would not have or reasonably be expected to result in a Material Adverse Effect and would not have or reasonably
be expected to result in any limitation or prohibition on the Company’s ability to register the Shares and Warrant Shares
for resale as set forth in the Registration Rights Agreement or any Purchaser’s ability to use Rule 144 to resell any Securities.
As of their respective filing dates, or to the extent corrected by a subsequent amendment, the SEC Reports complied in all material
respects with the requirements of the Securities Act and the Exchange Act and the rules and regulations of the Commission promulgated
thereunder, and none of the SEC Reports, when filed, contained any untrue statement of a material fact or omitted to state a material
fact required to be stated therein or necessary in order to make the statements therein, in light of the circumstances under which
they were made, not misleading. The Company has never been an issuer subject to Rule 144(i) under the Securities Act. Each
of the Material Contracts to which the Company or any Subsidiary is a party or to which the property or assets of the Company or
any of its Subsidiaries are subject has been filed (or incorporated by reference) as an exhibit to the SEC Reports, other than
the Transaction Documents.

 

(i)          Financial
Statements. The consolidated financial statements of the Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and regulations of the Commission with respect thereto as in effect at the
time of filing (or to the extent corrected by a subsequent amendment). Such consolidated financial statements have been prepared
in accordance with GAAP applied on a consistent basis during the periods involved, except as may be otherwise specified in such
financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required
by GAAP, and fairly present in all material respects the financial position of the Company and its consolidated Subsidiaries taken
as a whole as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in
the case of unaudited statements, to normal, immaterial year-end audit adjustments.

 

(j)          Material
Changes. Since the date of the latest financial statements included within the SEC Reports, except as specifically disclosed
in a subsequent SEC Report filed prior to the date hereof and except as disclosed in Schedule 3.1(j), (i) there have
been no events, occurrences or developments that have had or would reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect, (ii) the Company has not incurred any material liabilities (contingent or otherwise)
other than (A) trade payables and accrued expenses incurred in the ordinary course of business consistent with past practice and
(B) liabilities not required to be reflected in the Company’s consolidated financial statements pursuant to GAAP or required
to be disclosed in filings made with the Commission, (iii) the Company has not altered materially its method of accounting
or the manner in which it keeps its accounting books and records, (iv) the Company has not declared or made any dividend or
distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem
any shares of its capital stock (other than in connection with repurchases of unvested stock issued to employees of the Company),
and (v) the Company has not issued any equity securities to any officer, director or Affiliate, except Common Stock issued
in the ordinary course as dividends on outstanding preferred stock or issued pursuant to existing Company stock option or stock
purchase plans or executive and director compensation arrangements disclosed in the SEC Reports. Except as disclosed in Schedule
3.1(j) and except for the issuance of the Shares and Warrants contemplated by this Agreement, no event, liability or development
has occurred or exists with respect to the Company or its Subsidiaries or their respective business, properties, operations or
financial condition, that would be required to be disclosed by the Company under applicable securities laws at the time this representation
is made that has not been publicly disclosed at least one Trading Day prior to the date that this representation is made.

 

    	13

    	 

    

  

(k)          Litigation.
There is no Action which (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction
Documents or the Securities, or (ii) except as disclosed in Schedule 3.1(k), would, if there were an unfavorable decision,
individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. During the past five years,
neither the Company nor any Subsidiary, nor to the Company’s Knowledge any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach
of fiduciary duty. There has not been, and to the Company’s Knowledge there is not pending or contemplated, any investigation
by the Commission involving the Company or any current or former director or officer of the Company. During the past five years,
the Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by
the Company under the Exchange Act or the Securities Act.

 

(l)          Employment
Matters. No material labor dispute exists or, to the Company’s Knowledge, is imminent with respect to any of the employees
of the Company which would have or would reasonably be expected to result in a Material Adverse Effect. None of the Company’s
or any Subsidiary’s employees is a member of a labor union that relates to such employee’s relationship with the Company,
and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement. Except as disclosed in Schedule
3.1(l), no executive officer of the Company (as defined in Rule 405 of the Securities Act) has notified the Company or any
of its Subsidiaries that such officer intends to leave the Company or any such Subsidiary or otherwise terminate such officer’s
employment with the Company or any such Subsidiary. To the Company’s Knowledge, no executive officer or key employee is,
or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary
information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of
any third party, and to the Company’s Knowledge, the continued employment of each such executive officer or key employee
does not subject the Company or any Subsidiary to any liability with respect to any of the foregoing matters, except, in each case,
matters that, individually or in the aggregate, would not reasonably be expected to result in a Material Adverse Effect. The Company
is in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices,
terms and conditions of employment and wages and hours, except where the failure to be in compliance would not, individually or
in the aggregate, reasonably be expected to result in a Material Adverse Effect.

 

    	14

    	 

    

 

(m)          Compliance.
Neither the Company nor any of its Subsidiaries (i) is in default under or in violation of (and no event has occurred that
has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any of its Subsidiaries
under), nor has the Company or any of its Subsidiaries received written notice of a claim that it is in default under or that it
is in violation of, any Material Contract (whether or not such default or violation has been waived), (ii) is in violation
of any order of any court, arbitrator or governmental body having jurisdiction over the Company or any of its Subsidiaries or their
properties or assets, or (iii) is in violation of, or in receipt of written notice that it is in violation of, any statute,
rule or regulation of any governmental authority applicable to the Company or any of its Subsidiaries, except in each case as would
not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect.

 

(n)          Title
to Assets. The Company and each of its Subsidiaries has good and marketable title to all tangible personal property owned by
it that is material to its respective businesses, in each case free and clear of all Liens except such as do not materially affect
the value of such property and do not interfere with the use made and proposed to be made of such property by the Company. Any
real property and facilities held under lease by the Company or any of its Subsidiaries are held by them under valid, subsisting
and enforceable leases with such exceptions as are not material and do not interfere with the use made and proposed to be made
of such property and buildings by the Company and its Subsidiaries.

 

(o)          Patents
and Trademarks. Except as disclosed in Schedule 3.1(o), to the Company’s Knowledge, the Company and each of its
Subsidiaries owns, possesses, licenses or has other rights to use, all patents, patent applications, trade and service marks, trade
and service mark applications and registrations, trade names, trade secrets, inventions, copyrights, licenses, technology, know-how
and other intellectual property rights and similar rights necessary or material for use in connection with its respective businesses
as described in the SEC Reports and which the failure to so have would have or reasonably be expected to result in a Material Adverse
Effect (collectively, the “Intellectual Property Rights”). Except as disclosed in Schedule 3.1(o),
to the Company’s Knowledge, none of the Intellectual Property Rights used by the Company or any Subsidiary violates or infringes
upon the patent, trademark, copyright, trade secret or other proprietary rights of any Person. There is no pending or, to the Company’s
Knowledge, threatened action, suit, proceeding or claim by any Person that the Company’s or any Subsidiary’s business
as now conducted infringes or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of
another. To the Company’s Knowledge, there is no existing infringement by another Person of any of the Intellectual Property
Rights that would have or would reasonably be expected to result in a Material Adverse Effect. To the Company’s Knowledge,
all patent applications and patents within the Intellectual Property Rights have been prosecuted with a duty of candor, and, except
as disclosed in Schedule 3.1(o), there is no material fact known by the Company that would preclude the issuance of patents
with respect to said patent applications or that would render any issued patents invalid or unenforceable. There is no pending
or, to the Company’s Knowledge, threatened action, suit, proceeding or claim by another Person challenging the Company’s
or any Subsidiary’s rights in or to any material Intellectual Property Rights, or challenging inventorship, validity or scope
of any such Intellectual Property Rights. The Company has taken reasonable security measures to protect the secrecy, confidentiality
and value of all of its and its Subsidiaries’ Intellectual Property Rights, except where failure to do so would not, individually
or in the aggregate, reasonably be expected to result in a Material Adverse Effect. None of the technology employed by the Company
or any of its Subsidiaries has been obtained or is being used by the Company or any Subsidiary in violation of any contractual
obligation binding on the Company or any Subsidiary or, to the Company’s Knowledge, any of its or its Subsidiaries’
officers, directors or employees or otherwise in violation of the rights of any Person, which violations would have or would reasonably
be expected to have a Material Adverse Effect.

 

    	15

    	 

    

  

(p)          Insurance.
The Company and each of its Subsidiaries is insured by insurers of recognized financial responsibility against such losses and
risks and in such amounts as the Company believes to be prudent and customary in the businesses and locations in which the Company
and the Subsidiaries are engaged. None of the Company or any of its Subsidiaries has received any written notice of cancellation
of any such insurance, nor, to the Company’s Knowledge, will it or any Subsidiary be unable to renew its existing insurance
coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be necessary to continue
its business without a material increase in cost.

 

(q)          Transactions
with Affiliates and Employees. Except as set forth in the SEC Reports, none of the executive officers or directors of the Company
and, to the Company’s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company
(other than for services as employees, officers and directors) that would be required to be disclosed pursuant to Item 404 of Regulation
S-K promulgated under the Securities Act.

 

(r)          Internal
Accounting Controls. The Company maintains a system of internal accounting controls sufficient to provide reasonable assurance
that (i) transactions are executed in accordance with management’s general or specific authorizations, (ii) transactions
are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset and liability
accountability, (iii) access to assets or incurrence of liabilities is permitted only in accordance with management’s
general or specific authorization, and (iv) the recorded accountability for assets and liabilities is compared with the existing
assets and liabilities at reasonable intervals and appropriate action is taken with respect to any differences.

 

(s)          Sarbanes-Oxley;
Disclosure Controls. The Company is in compliance in all material respects with all of the provisions of the Sarbanes-Oxley
Act of 2002 which are applicable to it. The Company has established disclosure controls and procedures (as such term is defined
in Rule 13a-15(e) and 15d-15(e) under the Exchange Act) for the Company and designed such disclosure controls and procedures
to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is
recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. The
Company’s certifying officers have evaluated the effectiveness of the Company’s disclosure controls and procedures
as of the end of the period covered by the Company’s most recently filed periodic report under the Exchange Act (such date,
the “Evaluation Date”). The Company presented in its most recently filed periodic report under the Exchange
Act the conclusions of the certifying officers about the effectiveness of the disclosure controls and procedures based on their
evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the Company’s internal control
over financial reporting (as such term is defined in the Exchange Act) that have materially affected, or are reasonably likely
to materially affect, the Company’s internal control over financial reporting.

 

    	16

    	 

    

  

(t)          Certain
Fees. Except as disclosed in Schedule 3.1(t), no Person will have, as a result of the transactions contemplated by this
Agreement, any valid right, interest or claim against or upon the Company or a Purchaser for any commission, fee or other compensation
pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company, other than the Placement Agent
with respect to the offer and sale of the Shares and Warrants (which fees are being paid by the Company). The Purchasers shall
have no obligation with respect to any fees or with respect to any claim made by or on behalf of other Persons for fees of a type
contemplated in this paragraph (t) pursuant to any agreement to which the Company is a party that may be due in connection with
the transactions contemplated by the Transaction Documents. The Company shall indemnify, pay, and hold each Purchaser harmless
against, any liability, loss or expense (including, without limitation, attorneys’ fees and out-of-pocket expenses) arising
in connection with any such right, interest or claim; provided, that the Company shall not be responsible for the payment
of any amounts under this Agreement resulting from a breach of the representation of any Purchaser set forth in Section 3.2(h).

 

(u)          Private
Placement. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section 3.2, and
the accuracy of the information disclosed in the Accredited Investor Questionnaires provided by the Purchasers, no registration
under the Securities Act is required for the offer and sale of the Securities by the Company to the Purchasers under the Transaction
Documents. The issuance and sale of the Securities hereunder does not contravene the rules and regulations of the Principal Trading
Market.

 

(v)          Investment
Company. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the Shares and Warrants,
will not be or be an Affiliate of, an “investment company” within the meaning of the Investment Company Act of 1940,
as amended.

 

(w)          Registration
Rights. Other than each of the Purchasers pursuant to the Registration Rights Agreement, no Person has any right to cause the
Company to effect the registration under the Securities Act of any securities of the Company.

 

(x)          Listing
and Maintenance Requirements. The Company’s Common Stock is registered pursuant to Section 12(b) or 12(g) of
the Exchange Act, and the Company has taken no action designed to terminate the registration of the Common Stock under the Exchange
Act, nor has the Company received any notification that the Commission is contemplating terminating such registration. The Company
has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock
is listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading
Market. The Company is, and has no reason to believe that it will not in the foreseeable future continue to be in compliance with
all listing and maintenance requirements of the Principal Trading Market on the date hereof.

 

(y)          Application
of Takeover Protections; Rights Agreements. The Company and the Board of Directors have taken all necessary action, if any,
in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under
a rights agreement) or other similar anti-takeover provision under the Company’s charter documents or the laws of its state
of incorporation that is or could reasonably be expected to become applicable to any of the Purchasers as a result of the Purchasers
and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including, without limitation,
the Company’s issuance of the Securities and the Purchasers’ ownership of the Securities.

 

    	17

    	 

    

  

(z)          Disclosure.
The Company confirms that it has not provided, and none of its officers or directors nor, to the Company’s Knowledge, any
other Person acting on its or their behalf has provided, and it has not authorized the Placement Agent to provide, any Purchaser
or its respective agents or counsel with any information that it believes constitutes material, non-public information except insofar
as the existence, provisions and terms of the Transaction Documents and the proposed transactions hereunder may constitute such
information, all of which will be disclosed by the Company in the Press Release as contemplated by Section 4.5. The Company
understands and confirms that the Purchasers will rely on the foregoing representations in effecting transactions in securities
of the Company. All disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company, its business and
the transactions contemplated hereby, including the Disclosure Schedules to this Agreement, is true and correct in all material
respects and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to
make the statements made therein, in light of the circumstances under which they were made, not misleading. The Company acknowledges
and agrees that no Purchaser makes or has made any representations or warranties with respect to the transactions contemplated
hereby other than those specifically set forth in Section 3.2 or in the Accredited Investor Questionnaires provided by the
Purchasers.

 

(aa)         No
Integrated Offering. Assuming the accuracy of the Purchasers’ representations and warranties set forth in Section
3.2, neither the Company nor, to the Company’s Knowledge, any Person acting on its behalf has, directly or indirectly,
at any time within the past six months, made any offers or sales of any Company security or solicited any offers to buy any security
under circumstances that would (i) eliminate the availability of the exemption from registration under Regulation D under
the Securities Act in connection with the offer and sale by the Company of the Securities as contemplated hereby, or (ii) cause
the offering of the Securities pursuant to the Transaction Documents to be integrated with prior offerings by the Company for purposes
of any applicable law, regulation or stockholder approval provisions, including, without limitation, under the rules and regulations
of any Trading Market on which any of the securities of the Company are listed or designated unless such integration would not
have or reasonably be expected to result in a Material Adverse Effect.

 

(bb)         Tax
Matters. The Company and each of its Subsidiaries (i) has accurately and timely prepared and filed (or requested valid
extensions thereof) all foreign, federal and state income and all other tax returns, reports and declarations required by any jurisdiction
to which it is subject, (ii) has paid all taxes and other governmental assessments and charges that are material in amount,
shown or determined to be due on such returns, reports and declarations, except those being contested in good faith, with respect
to which adequate reserves have been set aside on the books of the Company, and (iii) has set aside on its books provisions
reasonably adequate for the payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations
apply, except, in the case of clauses (i) and (ii) above, where the failure to so pay or file any such tax, assessment,
charge or return would not have or reasonably be expected to result in a Material Adverse Effect. There are no unpaid taxes in
any material amount claimed to be due by the Company or any Subsidiary by the taxing authority of any jurisdiction.

 

    	18

    	 

    

  

(cc)         Environmental
Matters. To the Company’s Knowledge, none of the Company or any of its Subsidiaries (i) is in violation of any statute,
rule, regulation, decision or order of any governmental agency or body or any court, domestic or foreign, relating to the use,
disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure
to hazardous or toxic substances (collectively, “Environmental Laws”), (ii) owns or operates any
real property contaminated with any substance that is in violation of any Environmental Laws, (iii) is liable for any off-site
disposal or contamination pursuant to any Environmental Laws, or (iv) is subject to any claim relating to any Environmental
Laws; which violation, contamination, liability or claim has had or would reasonably be expected to have, individually or in the
aggregate, a Material Adverse Effect; and there is no pending investigation or, to the Company’s Knowledge, investigation
threatened in writing that might lead to such a claim.

 

(dd)         No
General Solicitation. Neither the Company nor, to the Company’s Knowledge, any person acting on behalf of the Company
has offered or sold any of the Securities by any form of general solicitation or general advertising.

 

(ee)         Off
Balance Sheet Arrangements. There is no transaction, arrangement, or other relationship between the Company, any Subsidiary
and an unconsolidated or other off balance sheet entity that is required to be disclosed by the Company in the SEC Reports and
is not so disclosed and would have or reasonably be expected to result in a Material Adverse Effect.

 

(ff)         Foreign
Corrupt Practices. Neither the Company nor any of its Subsidiaries, nor to the Company’s Knowledge, any agent or other
person acting on behalf of the Company or any of its Subsidiaries, has (i) directly or indirectly, used any funds for unlawful
contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic political activity, (ii) made
any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or
campaigns from corporate funds, (iii) failed to disclose fully any contribution made by the Company or any Subsidiary (or
made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv) violated in any
material respect any provision of the Foreign Corrupt Practices Act of 1977, as amended.

 

(gg)         Acknowledgment
Regarding Purchasers’ Purchase of Securities. The Company acknowledges and agrees that each of the Purchasers is acting
solely in the capacity of an arm’s length purchaser with respect to the Transaction Documents and the transactions contemplated
hereby and thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company
(or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby and any advice
given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the
transactions contemplated thereby is merely incidental to the Purchasers’ purchase of the Securities. The Company further
represents to each Purchaser that the Company’s decision to enter into this Agreement and the other Transaction Documents
has been based solely on the independent evaluation of the transactions contemplated hereby by the Company and its representatives.

 

    	19

    	 

    

 

(hh)        Regulation
M Compliance. The Company has not, and to the Company’s Knowledge no one acting on its behalf has, (i) taken, directly
or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the
Company to facilitate the sale or resale of any of the Securities, (ii) sold, bid for, purchased or paid any compensation
for soliciting purchases of, any of the Securities in violation of Regulation M under the Exchange Act, or (iii) paid or agreed
to pay to any Person any compensation for soliciting another to purchase any other securities of the Company, other than, in the
case of clauses (ii) and (iii), compensation paid to the Placement Agent in connection with the placement of the Shares and
Warrants.

 

(ii)         PFIC
Status. Neither the Company nor any of its Subsidiaries is or intends to become a “passive foreign investment company”
within the meaning of Section 1297 of the U.S. Internal Revenue Code of 1986, as amended.

 

(jj)         OFAC
Status. Neither the Company nor any of its Subsidiaries is and, to the Company’s Knowledge, no director, officer, agent,
employee, Affiliate or Person acting on behalf of the Company or any Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury Department (“OFAC”); and the Company will
not directly or indirectly use the proceeds of the sale of the Securities, or lend, contribute or otherwise make available such
proceeds to any joint venture partner or other Person or entity, towards any sales or operations in Cuba, Iran, Syria, Sudan, Myanmar
or any other country sanctioned by OFAC or for the purpose of financing the activities of any Person currently subject to any U.S.
sanctions administered by OFAC.

 

(kk)        Government
Licenses. The Company and its Subsidiaries possess such permits, certificates, licenses, approvals, consents and other authorizations
(collectively, “Governmental Licenses”) issued by the appropriate federal, state, local or foreign regulatory
agencies or bodies necessary to conduct their respective businesses as described in the SEC Reports, including without limitation,
all such approvals, certificates, authorizations and permits required by the United States Food and Drug Administration (the “FDA”)
and/or other federal, state, local or foreign agencies or bodies engaged in the regulation of clinical trials, pharmaceuticals,
or biohazardous substances or materials, except where the failure so to possess would not, individually or in the aggregate, have
or reasonably be expected to have a Material Adverse Effect; the Company and each of its Subsidiaries is in compliance with the
terms and conditions of all such Governmental Licenses, except where the failure so to comply would not, individually or in the
aggregate, have or reasonably be expected to have a Material Adverse Effect; all of the Governmental Licenses are valid and in
full force and effect, except when the invalidity of such Governmental Licenses or the failure of such Governmental Licenses to
be in full force and effect would not, individually or in the aggregate, have or reasonably be expected to have a Material Adverse
Effect; and neither the Company nor any of its Subsidiaries has received any written notice of Proceedings relating to the revocation
or modification of any such Governmental Licenses which, individually or in the aggregate, if the subject of an unfavorable decision,
ruling or finding, would have or reasonably be expected to have a Material Adverse Effect. Where required by applicable laws and
regulations of the FDA or any foreign regulatory authority, the Company and each of its Subsidiaries has submitted to the FDA or
any foreign regulatory authority an Investigational New Drug Application, or similar application, or amendment or supplement thereto
for a clinical trial it has conducted or sponsored or is conducting or sponsoring, except where such failure would not, individually
or in the aggregate, have or reasonably be expected to have a Material Adverse Effect; all such submissions were in material compliance
with applicable laws and rules and regulations when submitted and no material deficiencies have been asserted by the FDA or such
foreign regulatory authority with respect to any such submissions, except any deficiencies which could not, individually or in
the aggregate, have or reasonably be expected to have a Material Adverse Effect.

 

    	20

    	 

    

 

 

(ll)         No
Additional Agreements. The Company does not have any agreement or understanding with any Purchaser with respect to the transactions
contemplated by the Transaction Documents other than as specified in the Transaction Documents.

 

(mm)      No
Disqualification Events.  With respect to Securities to be offered and sold hereunder in reliance on Rule 506 under the
Securities Act (“Regulation D Securities”), none of the Company, any of its predecessors, any affiliated
issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial owner
of 20% or more of the Company’s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter
(as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at the time of sale (each,
an “Issuer Covered Person” and, together, “Issuer Covered Persons”) is subject
to any of the “Bad Actor” disqualifications described in Rule 506(d)(1)(i) to (viii) under the Securities Act (a “Disqualification
Event”), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable
care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to the extent
applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided
thereunder.

 

(nn)       Other
Covered Persons. Other than the Placement Agent, the Company is not aware of any person (other than any Issuer Covered Person)
that has been or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale
of any Regulation D Securities.

 

(oo)       Notice
of Disqualification Events. The Company will notify the Purchasers and the Placement Agent in writing, prior to the Closing
Date, of (i) any Disqualification Event relating to any Issuer Covered Person and (ii) any event that would, with the passage of
time, become a Disqualification Event relating to any Issuer Covered Person.

 

3.2         Representations
and Warranties of the Purchasers. Each Purchaser hereby, for itself and for no other Purchaser, represents and warrants as
of the date hereof and as of the Closing Date to the Company and the Placement Agent as follows:

 

    	21

    	 

    

 

(a)          Organization;
Authority. Such Purchaser is an entity duly organized, validly existing and in good standing under the laws of the jurisdiction
of its organization with the requisite corporate, limited liability company or partnership power and authority to enter into and
to consummate the transactions contemplated by the applicable Transaction Documents and otherwise to carry out its obligations
hereunder and thereunder. The execution and delivery of this Agreement by such Purchaser and the performance by such Purchaser
of the transactions contemplated by this Agreement have been duly authorized by all necessary corporate or, if such Purchaser is
not a corporation, such partnership, limited liability company or other applicable like action, on the part of such Purchaser.
Each Transaction Document to which it is a party has been duly executed by such Purchaser, and when delivered by such Purchaser
in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against
it in accordance with its terms, except as such enforceability may be limited by applicable bankruptcy, insolvency, reorganization,
moratorium, liquidation or similar laws relating to, or affecting generally the enforcement of, creditors’ rights and remedies
or by other equitable principles of general application.

 

(b)          No
Conflicts. The execution, delivery and performance by such Purchaser of this Agreement and the Registration Rights Agreement
and the consummation by such Purchaser of the transactions contemplated hereby and thereby will not (i) result in a violation
of the organizational documents of such Purchaser, (ii) conflict with, or constitute a default (or an event which with notice
or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Purchaser is a party, or (iii) result in a violation
of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such Purchaser,
except in the case of clauses (ii) and (iii) above, for such conflicts, defaults, rights or violations which would not,
individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such Purchaser to
perform its obligations hereunder.

 

(c)          Investment
Intent. Such Purchaser understands that the Securities are “restricted securities” and have not been registered
under the Securities Act or any applicable state securities law and is acquiring the Shares and Warrants and, upon exercise of
the Warrants, will acquire the Warrant Shares issuable upon exercise thereof as principal for its own account and not with a view
to, or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any applicable state
securities laws, provided, however, that by making the representations herein, such Purchaser does not agree to hold
any of the Securities for any minimum period of time and reserves the right, subject to the provisions of this Agreement and the
Registration Rights Agreement, at all times to sell or otherwise dispose of all or any part of such Securities pursuant to an effective
registration statement under the Securities Act or under an exemption from such registration and in compliance with applicable
federal and state securities laws. Such Purchaser is acquiring the Securities hereunder in the ordinary course of its business.
Such Purchaser does not presently have any agreement, plan or understanding, directly or indirectly, with any Person to distribute
or effect any distribution of any of the Securities (or any securities which are derivatives thereof) to or through any person
or entity; such Purchaser is not a registered broker-dealer under Section 15 of the Exchange Act or an entity engaged in a business
that would require it to be so registered as a broker-dealer.

 

(d)          Purchaser
Status. At the time such Purchaser was offered the Shares and Warrants, it was, and at the date hereof it is, and on the Closing
Date and on each date on which it exercises the Warrants it will be, an “accredited investor” as defined in Rule 501(a) under
the Securities Act.

 

(e)          General
Solicitation. Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication
regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or presented
at any seminar or any other general advertisement.

 

    	22

    	 

    

 

(f)          Experience
of Such Purchaser. Such Purchaser, either alone or together with its representatives, has such knowledge, sophistication and
experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment
in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is able to bear the economic risk
of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment.

 

(g)          Access
to Information. Such Purchaser acknowledges that it has had the opportunity to review the Transaction Documents (including
all exhibits and schedules thereto) and the Disclosure Materials and has been afforded (i) the opportunity to ask such questions
as it has deemed necessary of, and to receive answers from, representatives of the Company concerning the terms and conditions
of the offering of the Securities and the merits and risks of investing in the Securities, (ii) access to information about
the Company and its Subsidiaries and their respective financial condition, results of operations, business, properties, management
and prospects sufficient to enable it to evaluate its investment, and (iii) the opportunity to obtain such additional information
that the Company possesses or can acquire without unreasonable effort or expense that is necessary to make an informed investment
decision with respect to the investment. Neither such inquiries nor any other investigation conducted by or on behalf of such Purchaser
or its representatives or counsel shall modify, amend or affect such Purchaser’s right to rely on the truth, accuracy and
completeness of the Company’s representations and warranties contained in the Transaction Documents. Such Purchaser understands
that its investment in the Securities involves a high degree of risk. Such Purchaser has sought such accounting, legal and tax
advice as it has considered necessary to make an informed decision with respect to its acquisition of the Securities.

 

(h)          Brokers
and Finders. No Person will have, as a result of the transactions contemplated by this Agreement, any valid right, interest
or claim against or upon the Company or any Purchaser for any commission, fee or other compensation pursuant to any agreement,
arrangement or understanding entered into by or on behalf of such Purchaser.

 

(i)          Independent
Investment Decision. Such Purchaser has independently evaluated the merits of its decision to purchase Securities pursuant
to the Transaction Documents, and such Purchaser confirms that it has not relied on the advice of any other Purchaser’s business
and/or legal counsel in making such decision. Such Purchaser understands that nothing in this Agreement or any other materials
presented by or on behalf of the Company to the Purchaser in connection with the purchase of the Securities constitutes legal,
tax or investment advice. Such Purchaser has consulted such legal, tax and investment advisors as it, in its sole discretion, has
deemed necessary or appropriate in connection with its purchase of the Securities. Such Purchaser understands that the Placement
Agent has acted solely as the agent of the Company in this placement of the Shares and Warrants and such Purchaser has not relied
on the business or legal advice of the Placement Agent or any of its agents, counsel or Affiliates in making its investment decision
hereunder, and confirms that none of such Persons has made any representations or warranties to such Purchaser in connection with
the transactions contemplated by the Transaction Documents. Neither the Placement Agent nor any Affiliate of the Placement Agent
has made or makes any representation as to the Company or the quality of the Securities.  In connection with the issuance
of the Securities to such Purchaser, neither the Placement Agent nor any of its Affiliates has acted as a financial advisor or
fiduciary to such Purchaser.

 

    	23

    	 

    

  

(j)          Reliance
on Exemptions. Such Purchaser understands that the Securities are being offered and sold to it in reliance on specific exemptions
from the registration requirements of United States federal and state securities laws and that the Company is relying in part upon
the truth and accuracy of, and such Purchaser’s compliance with, the representations, warranties, agreements, acknowledgements
and understandings of such Purchaser set forth herein in order to determine the availability of such exemptions and the eligibility
of such Purchaser to acquire the Securities.

 

(k)          Certain
Trading Activities. Such Purchaser has not directly or indirectly engaged in any Short Sales involving the Company’s
securities since the time that it was first contacted by the Company with respect to the transactions contemplated hereby. “Short
Sales” include, without limitation, all “short sales” as defined in Rule 200 promulgated under Regulation
SHO under the Exchange Act and all types of direct and indirect stock pledges, forward sale contracts, options, puts, calls, short
sales, swaps and similar arrangements (including on a total return basis), and sales and other transactions through non-US broker
dealers or foreign regulated brokers. Notwithstanding the foregoing, in the case of a Purchaser that is or is part of a multi-managed
investment vehicle (a “Fund”) whereby separate portfolio managers manage separate portions of such Fund’s
assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Fund’s assets, the representation set forth above shall solely apply with respect to the portion of
assets of such Purchaser managed by the portfolio manager that made the investment decision to purchase the Securities covered
by this Agreement. Such Purchaser hereby covenants and agrees not to engage, directly or indirectly, in any transactions in the
securities of the Company or involving the Company’s securities during the period from the date hereof until such time as
(i) the transactions contemplated by this Agreement are first publicly announced as described in Section 4.5 or (ii) this
Agreement is terminated in full pursuant to Section 6.18. Notwithstanding the foregoing, for avoidance of doubt, nothing
contained herein shall constitute a representation or warranty, or preclude any actions, with respect to the identification of
the availability of, or securing of, available shares to borrow in order to effect short sales or similar transactions in the future.

 

(l)          No
Governmental Review. Such Purchaser understands that no United States federal or state agency or any other government or governmental
agency has passed on or made any recommendation or endorsement of the Securities or the fairness or suitability of the investment
in the Securities nor have such authorities passed upon or endorsed the merits of the offering of the Securities.

 

(m)         Residency.
Such Purchaser’s residence (if an individual) or offices in which its investment decision with respect to the Securities
was made (if an entity) are located at the address immediately below such Purchaser’s name on its signature page hereto.

 

(n)          Accuracy
of Accredited Investor Questionnaire. The Accredited Investor Questionnaire delivered by such Purchaser in connection with
this Agreement is complete and accurate in all respects as of the date of this Agreement and will be correct as of the Closing
Date.

 

    	24

    	 

    

 

(o)          Regulation
M Compliance. Such Purchaser is aware that the anti-manipulation rules of Regulation M under the Exchange Act may apply to
sales of Common Stock and other activities with respect to the Common Stock by the Purchasers, and agrees to comply with such rules.

 

The Company and each
of the Purchasers acknowledge and agree that no party to this Agreement has made or makes any representations or warranties with
respect to the transactions contemplated hereby other than those specifically set forth in this Article III and the Transaction
Documents.

 

ARTICLE
IV

OTHER AGREEMENTS OF THE PARTIES

 

4.1          Transfer
Restrictions.

 

(a)          Compliance
with Laws. Notwithstanding any other provision of this Article IV, each Purchaser, severally but not jointly, covenants that
the Securities may be disposed of only pursuant to an effective registration statement under, and in compliance with the requirements
of, the Securities Act, or pursuant to an available exemption from, or in a transaction not subject to, the registration requirements
of the Securities Act, and in compliance with any applicable state and federal securities laws. In connection with any transfer
of the Securities other than (i) pursuant to an effective registration statement, (ii) to the Company, (iii) pursuant
to Rule 144 (provided that such Purchaser provides the Company with reasonable assurances (in the form of seller and, if
applicable, broker representation letters) that the Securities may be sold pursuant to such rule), or (iv) in connection with
a bona fide pledge as contemplated in Section 4.1(b), the Company may require the transferor thereof to provide to the Company
an opinion of counsel selected by the transferor and reasonably acceptable to the Company, at the Company’s expense, the
form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such transfer does not
require registration of such transferred Securities under the Securities Act. As a condition of transfer, any such transferee shall
agree in writing to be bound by the terms of this Agreement and the Registration Rights Agreement and shall have the rights of
a Purchaser under this Agreement and the Registration Rights Agreement with respect to such transferred Securities.

 

(b)          Legends.
Certificates evidencing the Securities shall bear any legend as required by the “blue sky” laws of any state and a
restrictive legend in substantially the following form, until such time as they are not required under Section 4.1(c):

 

    	25

    	 

    

 

[NEITHER THESE SECURITIES
NOR THE SECURITIES ISSUABLE UPON EXERCISE OF THESE SECURITIES HAVE BEEN REGISTERED] [THESE SECURITIES HAVE NOT BEEN REGISTERED]
UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES
MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR THE
SECURITIES UNDER THE SECURITIES ACT OR (B) AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS
OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS OR BLUE SKY LAWS AS EVIDENCED BY A LEGAL OPINION
OF COUNSEL REASONABLY SATISFACTORY TO THE COMPANY AND ITS TRANSFER AGENT OR (II) UNLESS SOLD PURSUANT TO RULE 144 UNDER SAID ACT.

 

The Company acknowledges
and agrees that a Purchaser may from time to time pledge, and/or grant a security interest in, some or all of the legended Securities
in connection with applicable securities laws, pursuant to a bona fide margin agreement in compliance with a bona fide margin loan.
Such a pledge would not be subject to approval or consent of the Company and no legal opinion of legal counsel to the pledgee,
secured party or pledgor shall be required in connection with the pledge, but such legal opinion shall be required in connection
with a subsequent transfer or foreclosure following default by such Purchaser transferee of the pledge. No notice shall be required
of such pledge, but such Purchaser’s transferee shall promptly notify the Company of any such subsequent transfer or foreclosure
of such legended Securities. Each Purchaser acknowledges that the Company shall not be responsible for (i) any pledges relating
to, or the grant of any security interest in, any of the Securities or for any agreement, understanding or arrangement between
any Purchaser and its pledgee or secured party, or (ii) any violations of applicable securities laws that may result from
the sale of pledged shares as a result of the Purchaser holding material non-public information at the time of such sale. At the
appropriate Purchaser’s expense, the Company will execute and deliver such reasonable documentation as a pledgee or secured
party of Securities may reasonably request in connection with a pledge or transfer of the Securities, including the preparation
and filing of any required prospectus supplement under Rule 424(b)(3) of the Securities Act or other applicable provision
of the Securities Act to appropriately amend the list of selling stockholders thereunder. Each Purchaser acknowledges and agrees
that, except as otherwise provided in Section 4.1(c), any Securities subject to a pledge or security interest as contemplated
by this Section 4.1(b) shall continue to bear the legend set forth in this Section 4.1(b) and be subject
to the restrictions on transfer set forth in Section 4.1(a).

 

    	26

    	 

    

 

(c)          Removal
of Legends. The legend set forth in Section 4.1(b) above shall be removed and the Company shall issue a certificate
without such legend or any other legend to the holder of the applicable Securities upon which it is stamped or issue to such holder
by electronic delivery at the applicable balance account at the Depository Trust Company (“DTC”), if
(i) such Securities are registered for resale under the Securities Act (provided that, if a Purchaser is selling pursuant
to an effective Registration Statement, then such Purchaser agrees to only sell such Securities during such time that such Registration
Statement is effective and not withdrawn or suspended, and only as permitted by such Registration Statement), (ii) such Securities
are sold or transferred pursuant to Rule 144 (if the transferor is not an Affiliate of the Company), or (iii) such Securities
are eligible for sale under Rule 144, without the requirement for the Company to be in compliance with the current public information
required under Rule 144 as to such securities and without volume or manner-of-sale restrictions. Following the earlier of (A) the
Effective Date or (B) Rule 144 becoming available for the resale of such Securities, without the requirement for the Company
to be in compliance with the current public information required under Rule 144 as to such Securities and without volume or manner-of-sale
restrictions, the Company shall deliver to the Transfer Agent irrevocable instructions that the Transfer Agent shall reissue a
certificate representing the applicable Shares or issue a certificate representing the applicable Warrant Shares without legend
upon receipt by the Transfer Agent of the legended certificates for such Shares. Any fees (with respect to the Transfer Agent or
otherwise) associated with the removal of such legend shall be borne by the Company. Following the Effective Date, or at such earlier
time as a legend is no longer required for certain Securities (in which case a Purchaser shall also be required to provide reasonable
assurances (in the form of seller and, if applicable, broker representation letters) that a legend is no longer required), the
Company will, no later than three Trading Days following the delivery by a Purchaser to the Company or the Transfer Agent (with
notice to the Company) of (1) a legended certificate representing Shares or Warrant Shares (endorsed or with stock powers
attached, signatures guaranteed, and otherwise in form necessary to effect the reissuance and/or transfer thereof), or (2) an
Exercise Notice (as defined in the Warrants) and payment of the applicable exercise price in the manner stated in the applicable
Warrant to effect the exercise of such Warrant in accordance with its terms, and an opinion of counsel provided by, or at the expense,
of, the Company, to the extent required by Section 4.1(a), deliver or cause to be delivered to the transferee of such Purchaser
or such Purchaser, as applicable, a certificate representing such Securities that is free from all restrictive and other legends.
The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on
transfer set forth in this Section 4.1(c) other than to comply with applicable law. Certificates for Shares or Warrant
Shares subject to legend removal hereunder may be transmitted by the Transfer Agent to a Purchaser by crediting the account of
such Purchaser’s prime broker with DTC as directed by such Purchaser.

 

(d)          Irrevocable
Transfer Agent Instructions. The Company shall issue irrevocable instructions to the Transfer Agent, and any subsequent transfer
agent, in substantially the form of Exhibit D attached hereto (the “Irrevocable Transfer Agent Instructions”).
The Company represents and warrants that no instruction other than the Irrevocable Transfer Agent Instructions referred to in this
Section 4.1(d) (or instructions that are consistent therewith) will be given by the Company to the Transfer Agent in
connection with this Agreement, and that the Securities shall otherwise be freely transferable on the books and records of the
Company as and to the extent provided in this Agreement and the other Transaction Documents and applicable law. The Company acknowledges
that a breach by it of its obligations under this Section 4.1(d) will cause irreparable harm to a Purchaser. Accordingly,
the Company acknowledges that the remedy at law for a breach of its obligations under this Section 4.1(d) will be inadequate
and agrees, in the event of a breach or threatened breach by the Company of the provisions of this Section 4.1(d), that
a Purchaser shall be entitled, in addition to all other available remedies, to an order and/or injunction restraining any breach
and requiring immediate issuance and transfer, without the necessity of showing economic loss and without any bond or other security
being required.

 

    	27

    	 

    

 

(e)          Acknowledgement.
Each Purchaser, severally but not jointly, acknowledges its primary responsibilities under the Securities Act and accordingly will
not sell or otherwise transfer the Securities or any interest therein without complying with the requirements of the Securities
Act and applicable law. While the Registration Statement remains effective, each Purchaser hereunder may sell the Shares and Warrant
Shares in accordance with the plan of distribution contained in the Registration Statement and if it does so it will comply therewith
and with the related prospectus delivery requirements unless an exemption therefrom is available. Each Purchaser, severally and
not jointly with the other Purchasers, agrees that if it is notified by the Company in writing at any time that the Registration
Statement registering the resale of the Shares or the Warrant Shares is not effective or that the prospectus included in such Registration
Statement no longer complies with the requirements of Section 10 of the Securities Act, such Purchaser will refrain from selling
such Shares and Warrant Shares until such time as the Purchaser is notified by the Company that such Registration Statement is
effective or such prospectus is compliant with Section 10 of the Securities Act, unless such Purchaser is able to, and does, sell
such Shares or Warrant Shares pursuant to an available exemption from the registration requirements of Section 5 of the Securities
Act. Both the Company and its Transfer Agent, and their respective directors, officers, employees and agents, may rely on this
Section 4.1(e) and each Purchaser, severally but not jointly, with the other Purchasers will indemnify and hold harmless
each of such persons from any breaches or violations of this Section 4.1(e).

 

(f)          Buy-In.
If the Company shall fail for any reason or for no reason to issue to a Purchaser unlegended certificates within three Trading
Days after receipt of all documents necessary for the removal of the legend set forth above (the “Deadline Date”),
then, in addition to all other remedies available to such Purchaser, if on or after the Trading Day immediately following such
three Trading Day period, such Purchaser is required to purchase (in an open market transaction or otherwise) shares of Common
Stock to deliver in satisfaction of a sale by the holder of shares of Common Stock that such Purchaser anticipated receiving from
the Company without any restrictive legend (a “Buy-In”), then the Company shall, within three Trading
Days after such Purchaser’s request and in the Company’s sole discretion, either (i) pay cash to such Purchaser
in an amount equal to such Purchaser’s total purchase price (including brokerage commissions, if any) for the shares of Common
Stock so purchased (the “Buy-In Price”), at which point the shares of Common Stock held by such Purchaser
equal to the number of shares of Common Stock so purchased shall be forfeited to the Company and the Company’s obligation
to deliver such certificate (and to issue such shares of Common Stock) shall terminate, or (ii) promptly honor its obligation
to deliver to such Purchaser a certificate or certificates representing such shares of Common Stock and pay cash to the Purchaser
in an amount equal to the excess (if any) of the Buy-In Price over the product of (A) such number of shares of Common Stock, multiplied
by (B) the Closing Bid Price on the Deadline Date. A Purchaser shall provide the Company with written notice indicating the amounts
payable to such Purchaser in respect of the Buy-In, together with applicable confirmations and other evidence reasonably requested
by the Company.

 

(g)          Failure
to Timely Deliver. If the Company shall fail for any reason or for no reason to issue to a Purchaser unlegended certificates
by the Deadline Date, then, in addition to all other remedies available to such Purchaser, the Company shall pay to such Purchaser,
in cash, as partial liquidated damages and not as a penalty, $2,000 per Trading Day for each Trading Day after the Deadline Date
until such certificate is delivered without a legend.

 

4.2           Reservation
of Common Stock. The Company shall take all action necessary to at all times during the period the Warrants are outstanding
have authorized, and reserved for the purpose of issuance from and after the Closing Date, the number of shares of Common Stock
issuable upon exercise of the Warrants issued at the Closing (without taking into account any limitations on exercise of the Warrants
set forth in the Warrants).

 

    	28

    	 

    

 

4.3           Furnishing
of Information. In order to enable the Purchasers to sell the Securities under Rule 144, until the earlier of (a) the
date that the Securities cease to be Registrable Securities (as defined in the Registration Rights Agreement) (and for no less
than 12 months from the Closing), or (b) a Fundamental Transaction (as defined in the Warrants) pursuant to which the Company
is no longer a reporting company under the Exchange Act, the Company shall use its commercially reasonable efforts to timely file
(or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company
after the date hereof pursuant to the Exchange Act. Except as set forth in clause (b) above, during such period, if the Company
is not required to file reports pursuant to the Exchange Act, it will prepare and furnish to the Purchasers and make publicly available
in accordance with Rule 144(c) such information as is required for the Purchasers to sell the Securities under Rule 144.

 

4.4           No
Integration. The Company shall not, and shall use its commercially reasonable efforts to ensure that no Affiliate of the Company
shall, sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security (as defined in Section 2
of the Securities Act) that will be integrated with the offer or sale of the Securities in a manner that would require the registration
under the Securities Act of the sale of the Securities to the Purchasers, or that will be integrated with the offer or sale of
the Securities for purposes of the rules and regulations of any Trading Market such that it would require stockholder approval
prior to the closing of such other transaction unless stockholder approval is obtained before the closing of such subsequent transaction.

 

4.5           Securities
Laws Disclosure; Publicity. On or before 9:00 a.m., New York City time, on the Business Day immediately following the date
hereof, the Company shall issue a press release (the “Press Release”) reasonably acceptable to the Placement
Agent disclosing all material terms of the transactions contemplated hereby. On or before 5:30 p.m., New York City time, on the
fourth Trading Day immediately following the execution of this Agreement, the Company will file a Current Report on Form 8-K with
the Commission describing the terms of the Transaction Documents (and including as exhibits to such Current Report on Form 8-K
the material Transaction Documents (including, without limitation, this Agreement, the form of Warrant and the Registration Rights
Agreement)). Notwithstanding the foregoing, the Company shall not publicly disclose the name of any Purchaser or an Affiliate of
any Purchaser, or include the name of any Purchaser or an Affiliate of any Purchaser in any press release or filing with the Commission
(other than the Registration Statement) or any regulatory agency or Trading Market, without the prior written consent of such Purchaser,
except (a) as required by federal securities law in connection with (i) any registration statement contemplated by the
Registration Rights Agreement or (ii) the filing of final Transaction Documents (including signature pages thereto) with the
Commission, and (b) to the extent such disclosure is required by law, upon request of the Staff of the Commission or Trading
Market regulations, in which case the Company shall provide the Purchasers with prior written notice of such disclosure permitted
under this subclause (b). From and after the issuance of the Press Release, no Purchaser shall be in possession of any material,
non-public information received from the Company or any of its officers, directors, employees or agents, that is not disclosed
in the Press Release. Each Purchaser, severally and not jointly with the other Purchasers, covenants that it will comply with the
provisions of any confidentiality or nondisclosure agreement executed by it and, in addition, until such time as the transactions
contemplated by this Agreement are required to be publicly disclosed by the Company as described in this Section 4.5, such
Purchaser will maintain the confidentiality of all disclosures made to it in connection with this transaction (including the existence
and terms of this transaction).

 

    	29

    	 

    

 

4.6           Shareholder
Rights Plan. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any
Purchaser is an “Acquiring Person” under any control share acquisition, business combination, poison pill (including
any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company,
or that any Purchaser could be deemed to trigger the provisions of any such plan or arrangement, in either case solely by virtue
of receiving Securities under the Transaction Documents or under any other written agreement between the Company and the Purchasers.

 

4.7           Non-Public
Information. Except with respect to the material terms and conditions of the transactions contemplated by the Transaction Documents,
including this Agreement, or as expressly required by any applicable securities law, the Company covenants and agrees that neither
it, nor any other Person acting on its behalf, will provide any Purchaser or its agents or counsel with any information regarding
the Company that the Company believes constitutes material non-public information without the express written consent of such Purchaser,
unless prior thereto such Purchaser shall have executed a written agreement regarding the confidentiality and use of such information.
The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in
securities of the Company.

 

4.8           Use
of Proceeds. The Company shall use the net proceeds from the sale of the Shares and Warrants hereunder for working capital
and general corporate purposes.

 

    	30

    	 

    

 

4.9           Indemnification
of Purchasers. Subject to the provisions of this Section 4.9, the Company will indemnify and hold each Purchaser and
its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent
role of a Person holding such titles notwithstanding a lack of such title or any other title), each Person who controls such Purchaser
(within the meaning of Section 15 of the Securities Act and Section 20 of the Exchange Act), and the directors, officers, shareholders,
agents, members, partners or employees (and any other Persons with a functionally equivalent role of a Person holding such titles
notwithstanding a lack of such title or any other title) of such controlling persons (each, a “Purchaser Party”)
harmless from any and all losses, liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments,
amounts paid in settlements, court costs and reasonable attorneys’ fees and costs of investigation that any such Purchaser
Party may suffer or incur as a result of or relating to (a) any breach of any of the representations, warranties, covenants
or agreements made by the Company in this Agreement or in the other Transaction Documents or (b) any action instituted against
a Purchaser in any capacity, or any Purchaser Party, by any stockholder of the Company who is not an Affiliate of such Purchaser
seeking indemnification, with respect to any of the transactions contemplated by the Transaction Documents (unless such action
is based upon a breach of such Purchaser’s representations, warranties or covenants under the Transaction Documents or any
other agreement with the Company, or any agreements or understandings such Purchaser may have with any such stockholder or any
violations by the Purchaser of state or federal securities laws or any conduct by such Purchaser which constitutes fraud, gross
negligence, willful misconduct or malfeasance). Promptly after receipt by any such Person (the “Indemnified Person”)
of notice of any demand, claim or circumstances which would or might give rise to a claim or the commencement of any action, proceeding
or investigation in respect of which indemnity may be sought pursuant to this Section 4.9 such Indemnified Person shall
promptly notify the Company in writing and the Company shall assume the defense thereof, including the employment of counsel reasonably
satisfactory to such Indemnified Person, and shall assume the payment of all fees and expenses relating to such action, proceeding
or investigation; provided, however, that the failure of any Indemnified Person so to notify the Company shall not relieve
the Company of its obligations hereunder except to the extent that the Company is actually and materially prejudiced by such failure
to notify. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses
of such counsel shall be at the expense of such Indemnified Person unless: (i) the Company and the Indemnified Person shall
have mutually agreed to the retention of such counsel; (ii) the Company shall have failed promptly to assume the defense of
such proceeding and to employ counsel reasonably satisfactory to such Indemnified Person in such proceeding; or (iii) in the
reasonable judgment of counsel to such Indemnified Person, representation of both parties by the same counsel would be inappropriate
due to actual or potential differing interests between them, in which case the Company shall be responsible for the reasonable
fees and expenses of no more than one such separate counsel. The Company shall not be liable for any settlement of any proceeding
effected without its prior written consent, which consent shall not be unreasonably withheld, delayed or conditioned. Without the
prior written consent of the Indemnified Person, which consent shall not be unreasonably withheld, delayed or conditioned, the
Company shall not effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or
could have been a party and indemnity could have been sought hereunder by such Indemnified Person, unless such settlement includes
an unconditional release of such Indemnified Person from all liability arising out of such proceeding.

 

4.10         Listing
of Securities. In the time and manner required by the Principal Trading Market, the Company shall prepare and file with such
Principal Trading Market an additional shares listing application covering all of the Shares and Warrant Shares and shall use its
reasonable best efforts to take all steps necessary to cause all of the Shares and Warrant Shares to be approved for listing on
the Principal Trading Market as promptly as possible thereafter.

 

4.11         Form
D; Blue Sky. The Company agrees to timely file a Form D with respect to the Securities as required under Regulation D and to
provide a copy thereof, promptly upon the written request of any Purchaser. The Company, on or before the Closing Date, shall take
such action as the Company shall reasonably determine is necessary in order to obtain an exemption for or to qualify the Securities
for sale to the Purchasers at the Closing pursuant to this Agreement under applicable securities or “Blue Sky” laws
of the states of the United States (or to obtain an exemption from such qualification) and shall provide evidence of such actions
promptly upon the written request of any Purchaser.

 

    	31

    	 

    

 

4.12         Delivery
of Shares and Warrants on or before Closing. The Company shall deliver, or cause to be delivered, the respective Shares and
Warrants purchased by each Purchaser to or as directed by the Placement Agent on or prior to the Closing Date, for further delivery
by the Placement Agent to the applicable Purchaser upon Closing.

 

4.13         Subsequent
Equity Sales. From the date hereof until the earlier of (i) 60 days after the Effective Date of the Initial Registration Statement
(as defined in the Registration Rights Agreement) or (ii) January 3, 2016, the Company shall not issue shares of Common Stock or
Common Stock Equivalents; provided, however, that the 60-day period set forth in this Section 4.13 shall be
extended for the number of Trading Days during such period in which (a) trading in the Common Stock is suspended by any Trading
Market, or (b) following the Effective Date of the Initial Registration Statement, the Registration Statement is not effective
or the prospectus included in the Registration Statement may not be used by the Purchasers for the resale of the Shares and Warrant
Shares. Notwithstanding the foregoing, in no event shall this Section 4.13 prohibit the Company from issuing shares of Common
Stock or Common Stock Equivalents (i) in connection with acquisitions or strategic transactions (including joint ventures,
marketing or distribution arrangements, collaboration agreements or intellectual property license agreements) approved by a majority
of the disinterested directors of the Company; provided, that any such issuance shall only be to a Person which is, itself
or through its Subsidiaries, an operating company in a business synergistic with the business of the Company and in which the Company
receives benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities
primarily for the purpose of raising capital or to an entity whose primary business is investing in securities, (ii) upon
the exercise of any options, warrants or other convertible securities outstanding on the date hereof; provided, that the
terms and the conditions of the Securities are not amended after the date hereof in connection with any such issuance, (iii) upon
the exercise of the Warrants; provided, that the terms and the conditions of the Securities are not amended after the date
hereof in connection with any such issuance, or (iv) to employees, directors or consultants pursuant to any stock option,
equity incentive or employee stock purchase plan approved by a majority of the disinterested directors of the Company.

 

ARTICLE
V

CONDITIONS PRECEDENT TO CLOSING

 

5.1           Conditions
Precedent to the Obligations of the Purchasers to Purchase Securities. The obligation of each Purchaser to acquire Shares and
Warrants at the Closing is subject to the fulfillment to such Purchaser’s satisfaction, on or prior to the Closing Date,
of each of the following conditions, any of which may be waived by such Purchaser (as to itself only):

 

(a)          Representations
and Warranties. The representations and warranties of the Company contained in Section 3.1 shall be true and correct
in all material respects (other than representations and warranties which are already qualified as to materiality, which shall
be true and correct in all respects) as of the date when made and as of the Closing Date, as though made on and as of such date,
except for such representations and warranties that speak as of a specific date, which shall be true and correct as of such specified
date.

 

    	32

    	 

    

 

(b)          Performance.
The Company shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by it at or prior to the Closing.

 

(c)          No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

(d)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Securities at the Closing, all of which shall be and remain so long as necessary
in full force and effect.

 

(e)          Adverse
Change. Since the date of execution of this Agreement, no event or series of events shall have occurred that has had or would
reasonably be expected to have a Material Adverse Effect.

 

(f)           No
Suspensions of Trading in Common Stock. The Common Stock shall not have been suspended, as of the Closing Date, by the Commission
or the Principal Trading Market from trading on the Principal Trading Market nor shall suspension by the Commission or the Principal
Trading Market have been threatened, as of the Closing Date, either (i) in writing by the Commission or the Principal Trading
Market or (ii) by falling below the minimum listing maintenance requirements of the Principal Trading Market.

 

(g)          Company
Deliverables. The Company shall have delivered the Company Deliverables in accordance with Section 2.2(a).

 

(h)          Compliance
Certificate. The Company shall have delivered to each Purchaser a certificate, dated as of the Closing Date and signed by its
Chief Executive Officer or its Chief Financial Officer, certifying to the fulfillment of the conditions specified in Sections
5.1(a) and (b) in the form attached hereto as Exhibit G.

 

5.2           Conditions
Precedent to the Obligations of the Company to Sell Securities. The Company’s obligation to sell and issue the Shares
and Warrants at the Closing to the Purchasers is subject to the fulfillment to the satisfaction of the Company, on or prior to
the Closing Date, of the following conditions, any of which may be waived by the Company:

 

(a)           Representations
and Warranties. The representations and warranties made by the Purchasers in Section 3.2 shall be true and correct in
all material respects (other than representations and warranties which are already qualified as to materiality, which shall be
true and correct in all respects) as of the date when made, and as of the Closing Date as though made on and as of such date, except
for representations and warranties that speak as of a specific date, which shall be true and correct as of such specified date.

 

(b)           No
Injunction. No statute, rule, regulation, executive order, decree, ruling or injunction shall have been enacted, entered, promulgated
or endorsed by any court or governmental authority of competent jurisdiction that prohibits the consummation of any of the transactions
contemplated by the Transaction Documents.

 

    	33

    	 

    

 

(c)          Consents.
The Company shall have obtained in a timely fashion any and all consents, permits, approvals, registrations and waivers necessary
for consummation of the purchase and sale of the Securities at the Closing, all of which shall be and remain so long as necessary
in full force and effect.

 

(d)          Performance.
Such Purchaser shall have performed, satisfied and complied in all material respects with all covenants, agreements and conditions
required by the Transaction Documents to be performed, satisfied or complied with by such Purchaser at or prior to the Closing
Date.

 

(e)          Purchaser
Deliverables. Such Purchaser shall have delivered its Purchaser Deliverables in accordance with Section 2.2(b).

 

ARTICLE
VI

MISCELLANEOUS

 

6.1           Fees
and Expenses. Except as otherwise expressly set forth in the Company’s engagement letter with the Placement Agent, the
Company and each Purchaser, severally and not jointly with any other Purchaser, shall pay the fees and expenses of their respective
advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party in connection with the
negotiation, preparation, execution, delivery and performance of this Agreement; provided, that the Company shall reimburse the
lead Purchaser the sum of $15,000 at Closing for its legal expenses. Such sum may be withheld by the lead Purchaser from the Subscription
Amount otherwise payable at Closing. The Company shall pay all Transfer Agent fees, stamp taxes and other taxes and duties levied
in connection with the sale and issuance of the Securities to the Purchasers. Each Purchaser, severally and not jointly with any
other Purchaser, shall be responsible for all other tax liability that may arise as a result of holding or transferring the Securities
by it.

 

6.2           Entire
Agreement. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and supersede all prior agreements, understandings, discussions and representations,
oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules. At or after the Closing, and without further consideration, the Company and the Purchasers will execute and deliver
to the other such further documents as may be reasonably requested in order to give practical effect to the intention of the parties
under the Transaction Documents.

 

    	34

    	 

    

 

6.3           Notices.
Any and all notices or other communications or deliveries required or permitted to be provided hereunder shall be in writing and
shall be deemed given and effective on the earliest of (a) the date of transmission, if such notice or communication is delivered
via facsimile (provided the sender receives a machine-generated confirmation of successful transmission) at the facsimile number
specified in this Section 6.3 prior to 5:00 p.m., New York City time, on a Trading Day, (b) the next Trading Day after
the date of transmission, if such notice or communication is delivered via facsimile at the facsimile number specified in this
Section 6.3 on a day that is not a Trading Day or later than 5:00 p.m., New York City time, on any Trading Day, (c) the
Trading Day following the date of mailing, if sent by U.S. nationally recognized overnight courier service with next day delivery
specified, or (d) upon actual receipt by the party to whom such notice is required to be given. The address for such notices
and communications shall be as follows:

 

		If to the Company:	Transgenomic, Inc.

12325 Emmet Street

Omaha, NE 68164

Telephone No.: (402) 452-5400

Facsimile No.: (402) 452-5401

Attention: Chief Executive Officer

 

With a copy
to (which shall not constitute notice):

 

Paul Hastings LLP

1117 S. California Avenue

Palo Alto, California 94304

Telephone No.: (650) 320-1804

Facsimile No.: (650) 320-1904

Attention: Jeff Hartlin

 

		If to a Purchaser:	To
                                         the address set forth under such Purchaser’s name on the signature page hereof;

 

or such other address as may be designated in writing hereafter,
in the same manner, by such Person.

 

6.4           Amendments;
Waivers; No Additional Consideration. No provision of this Agreement may be waived, modified, supplemented or amended except
in a written instrument signed, in the case of an amendment, by the Company and the Purchasers holding or having the right to acquire
66 2/3% of the Shares and the Warrant Shares on a fully-diluted basis at the time of such amendment (which amendment shall be binding
on all Purchasers) or, in the case of a waiver, by the party against whom enforcement of any such waiver is sought; provided,
that any amendment, waiver modification or supplement of this Agreement that modifies the Subscription Amount of any Purchaser,
the Purchase Price or Section 2.1(a) or (c), Section 2.2, Section 3.1(z), Section 4.5 or
this Section 6.4 of this Agreement or causes any such Purchaser to assume any additional liability or material obligation,
may be effected only pursuant to a written instrument signed by the Company and such Purchaser. No waiver of any default with respect
to any provision, condition or requirement of this Agreement shall be deemed to be a continuing waiver in the future or a waiver
of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission
of either party to exercise any right hereunder in any manner impair the exercise of any such right. No consideration shall be
offered or paid to any Purchaser to amend or consent to a waiver or modification of any provision of any Transaction Document unless
the same consideration is also offered to all Purchasers who then hold Securities.

 

    	35

    	 

    

  

6.5           Construction.
The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit or affect
any of the provisions hereof. Any references to paragraphs, subparagraphs, sections or subsections are to those parts of this Agreement,
unless the context clearly indicates to the contrary. The language used in this Agreement will be deemed to be the language chosen
by the parties to express their mutual intent, and no rules of strict construction will be applied against any party. This Agreement
shall be construed as if drafted jointly by the parties, and no presumption or burden of proof shall arise favoring or disfavoring
any party by virtue of the authorship of any provisions of this Agreement or any of the Transaction Documents.

 

6.6           Successors
and Assigns. The provisions of this Agreement shall inure to the benefit of and be binding upon the parties and their successors
and permitted assigns. This Agreement, or any rights or obligations hereunder, may not be assigned by the Company without the written
consent of Purchasers holding or having the right to acquire 66 2/3% of the Shares and the Warrant Shares on a fully-diluted basis
at the time of such consent except to a successor in the event of a Fundamental Transaction. Any Purchaser may assign its rights
hereunder in whole or in part to any Person to whom such Purchaser assigns or transfers any Securities in compliance with the Transaction
Documents and applicable law, provided that such transferee shall agree in writing to be bound, with respect to the transferred
Securities, by the terms and conditions of this Agreement that apply to the “Purchasers”.

 

6.7           No
Third-Party Beneficiaries. This Agreement is intended for the benefit of the parties hereto and their respective successors
and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except (i) the
Placement Agent is an intended third party beneficiary of Article III hereof and (ii) each Purchaser Party is an intended
third party beneficiary of Section 4.9.

 

6.8           Governing
Law. All questions concerning the construction, validity, enforcement and interpretation of this Agreement shall be governed
by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of
conflicts of law thereof. Each party agrees that all Proceedings concerning the interpretations, enforcement and defense of the
transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its
respective Affiliates, employees or agents) shall be commenced exclusively in the New York Courts. Each party hereto hereby irrevocably
submits to the exclusive jurisdiction of the New York Courts for the adjudication of any dispute hereunder or in connection herewith
or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction
Documents), and hereby irrevocably waives, and agrees not to assert in any Proceeding, any claim that it is not personally subject
to the jurisdiction of any such New York Court, or that such Proceeding has been commenced in an improper or inconvenient forum.
Each party hereto hereby irrevocably waives personal service of process and consents to process being served in any such Proceeding
by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the
address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service
of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any manner
permitted by law. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
AND ALL RIGHT TO TRIAL BY JURY IN ANY LEGAL PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR THE TRANSACTIONS CONTEMPLATED
HEREBY.

 

    	36

    	 

    

  

6.9           Survival.
Unless this Agreement is terminated in accordance with Section 6.18, the representations, warranties agreements and covenants
contained herein shall survive the Closing and the delivery of the Securities, subject in each case to the applicable statute of
limitations.

 

6.10         Execution.
This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same
agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being
understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission,
or by e-mail delivery of a “.pdf” format data file, such signature shall create a valid and binding obligation of the
party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile signature page
were an original thereof.

 

6.11         Severability.
If any provision of this Agreement is held to be invalid or unenforceable in any respect, the validity and enforceability of the
remaining terms and provisions of this Agreement shall not in any way be affected or impaired thereby and the parties will attempt
to agree upon a valid and enforceable provision that is a reasonable substitute therefor, and upon so agreeing, shall incorporate
such substitute provision in this Agreement.

 

6.12         Rescission
and Withdrawal Right. Notwithstanding anything to the contrary contained in (and without limiting any similar provisions of)
the Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and
the Company does not timely perform its related obligations within the periods therein provided, then such Purchaser may rescind
or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election
in whole or in part without prejudice to its future actions and rights.

 

6.13         Replacement
of Securities. If any certificate or instrument evidencing any Securities is mutilated, lost, stolen or destroyed, the Company
shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof, or in lieu of and substitution
therefor, a new certificate or instrument, but only upon receipt of evidence reasonably satisfactory to the Company and the Transfer
Agent of such loss, theft or destruction and the execution by the holder thereof of a customary lost certificate affidavit of that
fact and an agreement to indemnify and hold harmless the Company and the Transfer Agent for any losses in connection therewith
or, if required by the Transfer Agent, a bond in such form and amount as is required by the Transfer Agent. The applicants for
a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs associated with the issuance
of such replacement Securities. If a replacement certificate or instrument evidencing any Securities is requested due to a mutilation
thereof, the Company may require delivery of such mutilated certificate or instrument as a condition precedent to any issuance
of a replacement.

 

    	37

    	 

    

  

6.14         Remedies.
In addition to being entitled to exercise all rights provided herein or granted by law, including recovery of damages, each of
the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that
monetary damages may not be adequate compensation for any loss incurred by reason of any breach of obligations described in the
foregoing sentence and hereby agree to waive in any action for specific performance of any such obligation (other than in connection
with any action for a temporary restraining order) the defense that a remedy at law would be adequate.

 

6.15         Payment
Set Aside. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction Document
or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or
exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside, recovered from,
disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other person
under any law (including, without limitation, any bankruptcy law, state or federal law, common law or equitable cause of action),
then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived
and continued in full force and effect as if such payment had not been made or such enforcement or setoff had not occurred.

 

6.16         Adjustments
in Share Numbers and Prices. In the event of any stock split, subdivision, dividend or distribution payable in shares of Common
Stock (or other securities or rights convertible into, or entitling the holder thereof to receive directly or indirectly shares
of Common Stock), combination or other similar recapitalization or event occurring after the date hereof and prior to the Closing,
each reference in any Transaction Document to a number of shares or a price per share shall be deemed to be amended to appropriately
account for such event.

 

6.17         Independent
Nature of Purchasers’ Obligations and Rights. The obligations of each Purchaser under any Transaction Document are several
and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance
of the obligations of any other Purchaser under any Transaction Document. The decision of each Purchaser to purchase Securities
pursuant to the Transaction Documents has been made by such Purchaser independently of any other Purchaser and independently of
any information, materials, statements or opinions as to the business, affairs, operations, assets, properties, liabilities, results
of operations, condition (financial or otherwise) or prospects of the Company or any Subsidiary which may have been made or given
by any other Purchaser or by any agent or employee of any other Purchaser, and no Purchaser and any of its agents or employees
shall have any liability to any other Purchaser (or any other Person) relating to or arising from any such information, materials,
statement or opinions. Nothing contained herein or in any Transaction Document, and no action taken by any Purchaser pursuant thereto,
shall be deemed to constitute the Purchasers as a partnership, an association, a joint venture or any other kind of entity, or
create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the
transactions contemplated by the Transaction Documents. Each Purchaser acknowledges that no other Purchaser has acted as agent
for such Purchaser in connection with making its investment hereunder and that no Purchaser will be acting as agent of such Purchaser
in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Purchaser
shall be entitled to independently protect and enforce its rights, including without limitation the rights arising out of this
Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Purchaser to be joined as an additional
party in any proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and
negotiation of the Transaction Documents. For reasons of administrative convenience only, Purchasers and their respective counsels
have chosen to communicate with the Company through Ellenoff Grossman & Schole LLP, counsel to the Placement Agent. Each Purchaser
acknowledges that Ellenoff Grossman & Schole LLP has rendered legal advice to the Placement Agent and not to such Purchaser
in connection with the transactions contemplated hereby, and that each such Purchaser has relied for such matters on the advice
of its own respective counsel. The Company has elected to provide all Purchasers with the same terms and Transaction Documents
for the convenience of the Company and not because it was required or requested to do so by any Purchaser.

 

    	38

    	 

    

  

6.18         Termination.
This Agreement may be terminated and the sale and purchase of the Shares and the Warrants abandoned at any time prior to the Closing
by either the Company or any Purchaser (with respect to itself only) upon written notice to the other, if the Closing has not been
consummated on or prior to 5:00 p.m., New York City time, on the Outside Date; provided, however, that the right
to terminate this Agreement under this Section 6.18 shall not be available to any Person whose failure to comply with its
obligations under this Agreement has been the cause of or resulted in the failure of the Closing to occur on or before such time.
Nothing in this Section 6.18 shall be deemed to release any party from any liability for any breach by such party of the
terms and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific
performance by any other party of its obligations under this Agreement or the other Transaction Documents. In the event of a termination
pursuant to this Section 6.18, the Company shall promptly notify all non-terminating Purchasers. Upon a termination in accordance
with this Section 6.18, the Company and the terminating Purchaser(s) shall not have any further obligation or liability
(including arising from such termination) to the other, and no Purchaser will have any liability to any other Purchaser under the
Transaction Documents as a result therefrom. The Company and any Purchaser(s) may extend the term of this Agreement in accordance
with the amendment provisions of Section 6.4.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	39

    	 

    

 

IN WITNESS WHEREOF,
the parties hereto have caused this Securities Purchase Agreement to be duly executed by their respective authorized signatories
as of the date first indicated above.

 

	 	TRANSGENOMIC, INC.
	 	 	 
	 	By:	 
	 	Name:	Paul Kinnon
	 	Title: 	President and Chief Executive Officer

 

[SIGNATURE PAGES
OF PURCHASERS FOLLOW]

 

[Signature Page to Securities Purchase
Agreement]

 

    	 

    	 

    

 

NAME OF PURCHASER: 

 

__________________________________________________

Name of Entity (if applicable)

 

By: ______________________________________________

Name:

Title:

 

Aggregate Share and Series A Warrant and Series B Warrant
Purchase Price (Subscription Amount): $_________________________________________________

 

Number of Shares to be Acquired: ______________

 

Underlying Shares Subject to Warrant: __________

(55% of the number of Shares and Series B Warrants to be acquired)

 

Number of Series B Warrants to be acquired:_________________

 

Tax ID No.: _______________________________________

 

Address for Notice/Residency of Purchaser:

 

c/o _______________________________________________

 

Street: ____________________________________________

 

City/State/Zip:
______________________________________

 

Attention: __________________________________________

 

Telephone No.: _____________________________________

 

Facsimile No.: ______________________________________

 

E-mail Address: ____________________________________

 

Delivery Instructions:

(if different than above)

 

c/o _______________________________

 

Street: ____________________________

 

City/State/Zip: _____________________

 

Attention: _________________________

 

Telephone No.: _____________________

 

 

[Signature Page to Securities Purchase
Agreement]EX-10.1

 Exhibit 10.1 

AMENDMENT NO. 2 TO EMPLOYMENT AGREEMENT 

This Amendment No. 2 to the Employment Agreement (this “Amendment No. 2”), is entered into as of June 30, 2015, by
and between Empire Resorts, Inc., a Delaware corporation (the “Company”), and Joseph A. D’Amato (the “Executive” and, together with the Company, “the Parties”). 

WITNESSETH: 

WHEREAS, Empire and Executive entered into an Employment Agreement dated as of November 26, 2012 (hereinafter and as amended, the
“Employment Agreement”); and 
 WHEREAS, Empire and Executive entered into an Amendment to the Employment Agreement dated
as of May 29, 2014 (“Amendment No. 1”); and 
 WHEREAS, the Parties desire to amend the Employment Agreement.

 NOW, THEREFORE, the Parties hereto agree to amend the Employment Agreement as follows, effective immediately: 

 

	 	1.	Section 1 shall be deleted in its entirety and replaced with the following: 

Term. The term of employment under this Agreement shall be for the period beginning on the Commencement Date (as defined in
the introductory paragraph of the Employment Agreement) and ending on the close of business on December 31, 2016 (the “Term”). If the Company is granted a gaming facility license by the New York State Gaming Commission with respect to
the Montreign Resort Casino (the “Gaming Facility License”), the Term shall be automatically extended to December 31, 2018 (the “Final End Date”). If the Company is not granted a Gaming Facility License by September 30,
2016, the Company shall notify the Executive on September 30, 2016 whether the Term shall be extended to the Final End Date. 
  

	 	2.	Section 6(b)(i) shall be deleted in its entirety and replaced with the following: 

 (i)
Housing Allowance. For the period from the Commencement Date until the Relocation Date (as defined herein), the Company agrees to pay to the Executive a housing allowance in the amount of $1,500 per month, payable no later than the end of the
next succeeding calendar month after the month to which the payment relates. Executive will be responsible for any taxes due on such allowance. For the period beginning on the date (the “Relocation Date”) the Company is awarded a
Gaming Facility License by the New York State Gaming Commission with respect to the Montreign Resort Casino (the “Casino Project”) and until the earlier of the (i) expiration of the Term or (ii) the completion of the Casino
Project, the Company shall provide the Executive with furnished housing in Sullivan County, New York that is mutually agreeable to the Company and Executive. Executive will be responsible for any taxes due on such housing expense incurred by
the Company on behalf of the Executive. In addition, the Executive shall be entitled to reimbursement of reasonable relocation expenses incurred in connection with the relocation to Sullivan County, New York. The Executive shall provide such
appropriate documentation regarding these expenses as the Company may reasonably request. 
 The Parties hereby agree that, except as
specifically provided in and modified by this Amendment No. 2, the Employment Agreement is in all other respects hereby ratified and confirmed and references to the Employment Agreement shall be deemed to refer to the Employment Agreement as
modified by this Amendment No. 2. 

  
 1 

 IN WITNESS WHEREOF, the undersigned have executed this Amendment as of the day and year first
written above. 
  

			
	EMPIRE RESORTS, INC.
		
	By:		 /s/ Laurette J. Pitts

	Name:		Laurette J. Pitts
	Title:		Executive Vice President, Chief Operating Officer and Chief Financial Officer
	
	EXECUTIVE
	
	 /s/ Joseph A. D’Amato

	Joseph A. D’Amato

  
 2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00247-of-00352.parquet"}]]